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What is New in the NARMS Report for 2007 
 
 
Data Presentation and Analysis  
 
In this report, major findings in 2007 are provided in the “Summary of NARMS 2007 Surveillance Data.” Tables 
presenting results for multiple years include the current year of reporting and previous 9 years. This report 
includes data for 1998 through 2007.   
 
Categories for Salmonella   
 
In previous reports, Salmonella isolates were categorized into non-Typhi Salmonella and Salmonella Typhi.  In 
this report, the terms non-typhoidal and typhoidal Salmonella are used for reporting purposes. Results for non-
typhoidal Salmonella are presented in Section 1 (Results).  Typhoidal Salmonella serotypes, which cause enteric 
fever, include Salmonella Typhi, Salmonella Paratyphi A, Salmonella Paratyphi B, and Salmonella Paratyphi C.  
Results for typhoidal Salmonella are presented in Section 2 (Results). 
 
Multidrug Resistance   
 
In previous reports, a multidrug resistance pattern, MDR-AmpC, was defined as resistance to at least ampicillin, 
chloramphenicol, streptomycin, sulfonamide, tetracycline, amoxicillin-clavulanic acid, and ceftiofur, and decreased 
susceptibility to ceftriaxone (MIC ≥2 μg/mL).  In this report, a new designation more descriptive of the resistance 
associated with this phenotype is used.  The new designation, ACSSuTAuCf, is defined as resistance to at least 
ampicillin, chloramphenicol, streptomycin, sulfonamide, tetracycline, amoxicillin-clavulanic acid, and ceftiofur.   
 
In this report, we are quantifying resistance to antimicrobial categories using classes defined by the Clinical and 
Laboratory Standards Institute (CLSI).  Cephems include ceftriaxone, ceftiofur (third-generation cephalosporins) 
and cefoxitin (cephamycin).  Folate pathway inhibitors include sulfisoxazole, sulfamethoxazole (sulfonamides), 
and trimethoprim-sulfamethoxazole.  In previous reports, we quantified resistance by categories that included 
CLSI classes and subclasses.  
 
Trends in Antimicrobial Resistance: NARMS Data  
 
In previous reports, a summary of trend analysis of the proportion of specific resistance phenotypes among non-
Typhi Salmonella, Salmonella Typhi and Campylobacter was included.  In this report, NARMS data are displayed 
graphically in the “Summary of NARMS 2007 Surveillance Data” section.  The figures display resistance from 
1996-2007 for non-typhoidal Salmonella, 1999-2007 for Salmonella ser. Typhi, and 1999-2007 for 
Campylobacter.  
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Introduction 
 
 
The National Antimicrobial Resistance Monitoring System (NARMS) for Enteric Bacteria is a collaboration among 
the Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA-CVM), and U.S. 
Department of Agriculture (USDA).  The primary purpose of NARMS at CDC is to monitor antimicrobial resistance 
among foodborne enteric bacteria isolated from humans.  Other components of the interagency NARMS program 
include surveillance for resistance in enteric bacterial pathogens isolated from foods, conducted by the FDA 
Center for Veterinary Medicine 
(http://www.fda.gov/AnimalVeterinary/SafetyHealth/AntimicrobialResistance/NationalAntimicrobialResistanceMoni
toringSystem/default.htm), and resistance in enteric pathogens isolated from animals, conducted by the USDA 
Agricultural Research Services (http://www.ars.usda.gov/main/site_main.htm?modecode=66-12-05-08).   
 
Many NARMS activities are conducted within the framework of CDC’s Emerging Infections Program (EIP), 
Epidemiology and Laboratory Capacity (ELC) Program, and the Foodborne Diseases Active Surveillance Network 
(FoodNet).  In addition to surveillance of resistance in enteric pathogens, the NARMS program at CDC also 
includes public health research into the mechanisms of resistance, education efforts to promote prudent use of 
antimicrobial agents, and studies of resistance in commensal organisms. 
 
Before NARMS was established, CDC monitored antimicrobial resistance in Salmonella, Shigella, and 
Campylobacter through periodic surveys of isolates from a panel of sentinel counties. NARMS at CDC began in 
1996 with prospective monitoring of antimicrobial resistance among clinical non-Typhi Salmonella and 
Escherichia coli O157 isolates in 14 sites. In 1997, testing of clinical Campylobacter isolates was initiated in the 
five sites participating in FoodNet. Testing of clinical Salmonella enterica serotype Typhi and Shigella isolates was 
added in 1999. Since 2003, all 50 states have been forwarding a representative sample of non-Typhi Salmonella, 
Salmonella ser. Typhi, Shigella, and E. coli O157 isolates to NARMS for antimicrobial susceptibility testing, and 
10 FoodNet states have been participating in Campylobacter surveillance. 
 
This annual report includes CDC’s surveillance data for 2007 for non-typhoidal Salmonella, typhoidal Salmonella, 
Shigella, Campylobacter and E. coli O157 isolates. Data for earlier years are presented in tables when 
appropriate.  Antimicrobial classes defined by Clinical and Laboratory Standards Institute (CLSI) are used in data 
presentation and analysis. CLSI classes constitute major classifications of antimicrobial agents, e.g., 
aminoglycosides and cephems. 
 
This report also includes World Health Organization’s categorization of antimicrobials of critical importance to 
human medicine (Table I).   
 
Additional NARMS data and more information about NARMS activities are available at http://www.cdc.gov/narms  
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WHO Categorization of Antimicrobial Agents  
 
 
In 2005, the World Health Organization (WHO) convened a panel of experts to develop a list of essential 
antimicrobial agents according to their importance to human medicine.  The participants categorized antimicrobial 
agents as either Critically Important, Highly Important, or Important based upon two criteria: (1) sole therapies or 
one of the few alternatives to treat serious human diseases and (2) used to treat disease caused by organisms 
that may be transmitted via non–human sources or diseases caused by organisms that may acquire resistance 
genes from non–human sources. 
 
• Antimicrobial agents are considered critically important if both criteria (1) and (2) are true. 
• Antimicrobial agents are highly important if either criterion (1) or (2) is true. 
• Antimicrobial agents are important if neither criterion is true. 
 
Table I:  WHO categorization of antimicrobials of critical importance to human medicine 
WHO 
Category 
Level 
 
Importance CLSI Class Antimicrobial Agent tested in NARMS 
I Critically important 
Aminoglycosides 
Amikacin 
Gentamicin 
Streptomycin 
β-lactam / β-lactamase inhibitor 
combinations Amoxicillin-clavulanic acid 
Cephems  Ceftriaxone 
Ketolides Telithromycin 
Macrolides 
Azithromycin 
Erythromycin 
Penicillins Ampicillin 
Quinolones 
Ciprofloxacin 
Nalidixic acid 
 
II Highly important 
Aminoglycosides Kanamycin 
Cephems 
Cefoxitin 
Cephalothin 
Folate pathway inhibitors 
Sulfamethoxazole / Sulfisoxazole 
Trimethoprim-sulfamethoxazole 
Phenicols Chloramphenicol 
Tetracyclines Tetracycline 
 
III Important Lincosamides Clindamycin 
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Summary of NARMS 2007 Surveillance Data  
 
 
Population 
 
In 2007, all 50 states participated in NARMS, representing the entire population of approximately 302 million 
persons (Table II). Surveillance was conducted in all states for Escherichia coli O157, non-typhoidal Salmonella, 
typhoidal Salmonella, and Shigella. For Campylobacter, surveillance was conducted in 10 states that comprise 
the Foodborne Diseases Active Surveillance Network (FoodNet), representing approximately 46 million persons 
(15.0% of the U.S. population). 
 
Clinically Important Antimicrobial Resistance Patterns 
 
In the United States, fluoroquinolones and third-generation cephalosporins (e.g., ceftriaxone) are commonly used 
to treat severe Salmonella infections, including Salmonella ser. Typhi, the organism that causes typhoid 
fever.Fluoroquinolones are also used to treat Campylobacter infections.  
 
In Enterobacteriaceae, resistance to nalidixic acid, an elementary quinolone, correlates with decreased 
susceptibility to ciprofloxacin (MIC ≥0.12 μg/mL) and possible fluoroquinolone treatment failure. Ceftiofur is a 
third-generation cephalosporin used in food animals in the United States; resistance to ceftiofur among 
Enterobacteriaceae correlates with decreased susceptibility to ceftriaxone (MIC ≥2 μg/mL). A substantial 
proportion of isolates tested by NARMS in 2007 demonstrated resistance to these clinically important 
antimicrobial agents, as follows: 
• 26.0% (286/1100) of Campylobacter isolates were resistant to ciprofloxacin, including 
o 28.6% (30/105) of Campylobacter coli isolates  
o 25.8% (256/992) of Campylobacter jejuni isolates 
• 2.2% (48/2144) of non-typhoidal Salmonella isolates were resistant to nalidixic acid, including 
o 5.7% (22/385) of Salmonella ser. Enteritidis isolates  
o Enteritidis was the most common serotype among nalidixic acid–resistant non-typhoidal 
Salmonella isolates: 45.8% (22/48) of nalidixic acid–resistant isolates were serotype Enteritidis. 
• 3.3% (70/2144) of non-typhoidal Salmonella isolates were resistant to ceftiofur, including 
o 7.7% (17/220) of Salmonella ser. Newport isolates  
o Typhimurium was the most common serotype among ceftiofur–resistant non-typhoidal Salmonella 
isolates: 35.7% (25/70) of ceftiofur–resistant isolates were serotype Typhimurium. 
• 62.3% (248/398) of Salmonella ser. Typhi isolates were resistant to nalidixic acid. 
• 1.9% (9/482)) of Shigella isolates were resistant to nalidixic acid and a single (1/61) S. flexneri isolate was 
resistant to ciprofloxacin. 
• 2.1% (4/190) of E. coli O157 isolates were resistant to nalidixic acid and a single (1/190) isolate was resistant 
to ciprofloxacin. 
• No ceftiofur or ceftriaxone resistant Shigella or E. coli O157 isolates were observed in 2007. 
 
Multidrug Resistance 
 
Multidrug resistance is described in NARMS by the number of antimicrobial classes and also by specific 
coresistant phenotypes. CLSI classes of antimicrobial agents are used in this report (Table III, Table IV).  For non-
typhoidal Salmonella, a common multidrug-resistant phenotype in 2007 includes resistance to at least ampicillin, 
chloramphenicol, streptomycin, sulfonamide (sulfamethoxazole/sulfisoxazole), and tetracycline (ACSSuT). The 
ACSSuT phenotype includes resistance to five antimicrobial classes. Another common phenotype includes 
resistance to at least ampicillin, chloramphenicol, streptomycin, sulfonamide, tetracycline, amoxicillin-clavulanic 
acid, and ceftiofur (ACSSuTAuCf).The ACSSuTAuCf phenotype includes resistance to 7 antimicrobial classes. 
• 18.9% (406/2144) of non-typhoidal Salmonella isolates were resistant to one or more CLSI classes, and  
11.1% (239/2144) were resistant to three or more CLSI classes. 
o 34.2% (138/403) of Salmonella ser. Typhimurium isolates were resistant to three or more classes.  
o 10.5% (23/220) of Salmonella ser. Newport isolates were resistant to three or more classes. 
o 1.0% (4/385) of Salmonella ser. Enteritidis isolates were resistant to three or more classes. 
o Of 239 non-typhoidal Salmonella resistant to three or more classes, most were Salmonella ser. 
Typhimurium (57.7%). 
• 6.3% (136/2144) of non-typhoidal Salmonella isolates had the ACSSuT resistance pattern, including 
o 22.6% (91/403) of Salmonella ser. Typhimurium isolates, and 
o 8.2% (18/220) of Salmonella ser. Newport isolates. 
• 2.1% (46/2144) of non- typhoidal Salmonella isolates had the ACSSuTAuCf resistance pattern, including 
o 7.7% (17/220) of Salmonella ser. Newport isolates, and 
o 3.5% (14/403) of Salmonella ser. Typhimurium isolates. 
• 33.2% (160/482) of Shigella isolates were resistant to three or more classes. 
• 2.1% (4/190) of E. coli O157 isolates were resistant to three or more classes. 
 
 
Trends in Antimicrobial Resistance: NARMS Data 
 
The following figures display resistance from 1996-2007 for non-typhoidal Salmonella, 1999-2007 for Salmonella 
ser. Typhi and 1997-2007 for Campylobacter. 
 
Figure 1.01: Proportion of non-typhoidal Salmonella isolates resistant to nalidixic acid, by year, 1996-2007. 
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Figure 1.02: Proportion of non-typhoidal Salmonella isolates resistant to ceftiofur, by year, 1996-2007. 
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Figure 1.03: Proportion of Salmonella ser. Enteritidis isolates resistant to nalidixic acid, by year, 1996-2007. 
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Figure 1.04: Proportion of Salmonella ser. Typhimurium isolates resistant to at least ampicillin, chloramphenicol, 
streptomycin, sulfonamide, and tetracycline (ACSSuT), by year, 1996-2007. 
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Figure 1.05: Proportion of Salmonella ser. Newport isolates resistant to at least ampicillin, chloramphenicol, 
streptomycin, sulfonamide, tetracycline, amoxicillin-clavulanic acid, and ceftiofur (ACSSuTAuCf), by year, 1996-
2007. 
Pr
op
or
tio
n 
R
es
is
ta
nt
 
 
17 
Figure 1.06: Proportion of non-typhoidal Salmonella isolates resistant to 1 or more antimicrobial classes, by year, 
1996-2007. 
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Figure 1.07: Proportion of non-typhoidal Salmonella isolates resistant to 3 or more antimicrobial classes, by year, 
1996-2007. 
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Figure 1.08: Proportion of Salmonella ser. Typhi isolates resistant to nalidixic acid, by year, 1999-2007. 
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Figure 1.09: Proportion of Campylobacter isolates resistant to ciprofloxacin, by year, 1997-2007. 
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Table II:  Population size and number of isolates received and tested, NARMS, 2007 
 
n (%) n (%) n (%) n (%) n (%)
Alabama 4,627,851 60 (2.8%) 1 (0.2%) 39 (8.1%) 4 (2.1%)
Alaska 683,478 5 (0.2%) 1 (0.2%) 1 (0.2%) 2 (1.1%)
Arizona 6,338,755 64 (3.0%) 7 (1.7%) 23 (4.8%) 3 (1.6%)
Arkansas 2,834,797 34 (1.6%) 0 (0.0%) 4 (0.8%) 1 (0.5%)
California§ 26,674,661 206 (9.6%) 57 (13.7%) 2 (0.4%) 12 (6.3%) 59 (5.4%)
Colorado 4,861,515 31 (1.4%) 7 (1.7%) 7 (1.5%) 5 (2.6%) 57 (5.2%)
Connecticut 3,502,309 26 (1.2%) 10 (2.4%) 3 (0.6%) 3 (1.6%) 98 (8.9%)
Delaw are 864,764 8 (0.4%) 2 (0.5%) 0 (0.0%) 0 (0.0%)
District of Columbia 588,292 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Florida 18,251,243 34 (1.6%) 11 (2.7%) 0 (0.0%) 0 (0.0%)
Georgia 9,544,750 118 (5.5%) 18 (4.3%) 59 (12.2%) 37 (19.5%) 313 (28.5%)
Haw aii 1,283,388 25 (1.2%) 4 (1.0%) 1 (0.2%) 1 (0.5%)
Houston, Texas¶ 4,858,315 40 (1.9%) 6 (1.4%) 22 (4.6%) 2 (1.1%)
Idaho 1,499,402 10 (0.5%) 1 (0.2%) 0 (0.0%) 4 (2.1%)
Illinois 12,852,548 101 (4.7%) 16 (3.9%) 38 (7.9%) 6 (3.2%)
Indiana 6,345,289 39 (1.8%) 2 (0.5%) 3 (0.6%) 4 (2.1%)
Iow a 2,988,046 23 (1.1%) 1 (0.2%) 5 (1.0%) 2 (1.1%)
Kansas 2,775,997 18 (0.8%) 0 (0.0%) 2 (0.4%) 2 (1.1%)
Kentucky 4,241,474 34 (1.6%) 0 (0.0%) 22 (4.6%) 6 (3.2%)
Los Angeles** 9,878,554 55 (2.6%) 19 (4.6%) 5 (1.0%) 0 (0.0%)
Louisiana 4,293,204 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Maine 1,317,207 7 (0.3%) 0 (0.0%) 1 (0.2%) 1 (0.5%)
Maryland 5,618,344 60 (2.8%) 12 (2.9%) 5 (1.0%) 0 (0.0%) 75 (6.8%)
Massachusetts 6,449,755 56 (2.6%) 16 (3.9%) 7 (1.5%) 4 (2.1%)
Michigan 10,071,822 42 (2.0%) 6 (1.4%) 3 (0.6%) 3 (1.6%)
Minnesota 5,197,621 35 (1.6%) 8 (1.9%) 11 (2.3%) 8 (4.2%) 154 (14.0%)
Mississippi 2,918,785 40 (1.9%) 0 (0.0%) 41 (8.5%) 2 (1.1%)
Missouri 5,878,415 29 (1.4%) 1 (0.2%) 15 (3.1%) 4 (2.1%)
Montana 957,861 8 (0.4%) 0 (0.0%) 1 (0.2%) 1 (0.5%)
Nebraska 1,774,571 9 (0.4%) 1 (0.2%) 6 (1.2%) 4 (2.1%)
Nevada 2,565,382 15 (0.7%) 0 (0.0%) 2 (0.4%) 1 (0.5%)
New  Hampshire 1,315,828 11 (0.5%) 4 (1.0%) 0 (0.0%) 1 (0.5%)
New  Jersey 8,685,920 57 (2.7%) 32 (7.7%) 11 (2.3%) 10 (5.3%)
New  Mexico 1,969,915 28 (1.3%) 0 (0.0%) 7 (1.5%) 4 (2.1%) 56 (5.1%)
New  York†† 11,023,202 69 (3.2%) 20 (4.8%) 5 (1.0%) 8 (4.2%) 130 (11.8%)
New  York City‡‡ 8,274,527 77 (3.6%) 64 (15.4%) 6 (1.2%) 5 (2.6%)
North Carolina 9,061,032 87 (4.1%) 11 (2.7%) 3 (0.6%) 3 (1.6%)
North Dakota 639,715 4 (0.2%) 0 (0.0%) 1 (0.2%) 1 (0.5%)
Ohio 11,466,917 69 (3.2%) 13 (3.1%) 20 (4.1%) 3 (1.6%)
Oklahoma 3,617,316 36 (1.7%) 3 (0.7%) 7 (1.5%) 2 (1.1%)
Oregon 3,747,455 18 (0.8%) 4 (1.0%) 4 (0.8%) 5 (2.6%) 109 (9.9%)
Pennsylvania 12,432,792 94 (4.4%) 9 (2.2%) 7 (1.5%) 3 (1.6%)
Rhode Island 1,057,832 7 (0.3%) 2 (0.5%) 2 (0.4%) 0 (0.0%)
South Carolina 4,407,709 53 (2.5%) 1 (0.2%) 7 (1.5%) 0 (0.0%)
South Dakota 796,214 9 (0.4%) 0 (0.0%) 4 (0.8%) 2 (1.1%)
Tennessee 6,156,719 81 (3.8%) 1 (0.2%) 19 (3.9%) 3 (1.6%) 49 (4.5%)
Texas§§ 19,046,065 59 (2.8%) 13 (3.1%) 10 (2.1%) 2 (1.1%)
Utah 2,645,330 12 (0.6%) 3 (0.7%) 1 (0.2%) 3 (1.6%)
Vermont 621,254 4 (0.2%) 0 (0.0%) 0 (0.0%) 1 (0.5%)
Virginia 7,712,091 71 (3.3%) 25 (6.0%) 9 (1.9%) 4 (2.1%)
Washington 6,468,424 6 (0.3%) 0 (0.0%) 1 (0.2%) 0 (0.0%)
West Virginia 1,812,035 1 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Wisconsin 5,601,640 51 (2.4%) 3 (0.7%) 26 (5.4%) 6 (3.2%)
Wyoming 522,830 8 (0.4%) 0 (0.0%) 4 (0.8%) 2 (1.1%)
Total 301,621,157 2144 (100.0%) 415 (100.0%) 482 (100.0%) 190 (100.0%) 1100 (100.0%)
* US Census Bureau, 2007
† Typhoidal Salmonella  includes Typhi, Paratyphi A, Paratyphi B, and Paratyphi C 
‡ Campylobacter isolates are submitted only from FoodNet sites represent ing a total populat ion 45,954,593. All Campylobacter isolates are received from Georgia, M aryland,
  New M exico, Oregon, and Tennessee and every other isolate from California, Colorado, Connecticut , and New York; and every f if th isolate f rom M innesota.
§ Excluding Los Angeles County
¶ Houston City
** Los Angeles County
†† Excluding New York City
‡‡ Five burroughs of New York City (Bronx, Brooklyn, M anhattan, Queens, Staten Island)
§§ Excluding Houston, Texas
Shigella E. coli  O157 Campylobacter ‡
State/Site Population Size *
Non-typhoidal
Salmonella
Typhoidal† 
Salmonella 
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Surveillance and Laboratory Testing Methods  
 
 
Surveillance Sites and Isolate Submissions  
 
In 2007, NARMS conducted nationwide surveillance among approximately 302 million persons (2007 U.S. 
Census Bureau estimates). Public health laboratories systematically selected every 20th non-Typhi Salmonella 
(i.e., all Salmonella serotypes except serotype Typhi), Shigella, and Escherichia coli O157 isolate as well as every 
Salmonella ser. Typhi isolate received at their laboratories and forwarded these isolates to CDC for antimicrobial 
susceptibility testing. Salmonella Paratyphi A, Paratyphi B, and Paratyphi C were included in the every 20th 
sampling for non-Typhi Salmonella. 
 
The following scheme for Campylobacter isolate submission has been used since 2005: Public health laboratories 
of the 10 state health departments that participated in CDC’s Foodborne Diseases Active Surveillance Network 
(FoodNet) forwarded a representative sample of Campylobacter isolates to CDC for susceptibility testing. The 
FoodNet sites, representing approximately 45 million persons (2006 U.S. Census Bureau estimates), included 
California, Colorado, Connecticut, Georgia, Maryland, Minnesota, New Mexico, New York, Oregon, and 
Tennessee.  Depending on burden of Campylobacter in each FoodNet site, one of three methods was used to 
obtain a representative sample of Campylobacter isolates: all isolates received by Georgia, Maryland, New 
Mexico, Oregon, and Tennessee; every other isolate from California, Colorado, Connecticut, and New York; and 
every fifth isolate from Minnesota. From 1997 to 2004, one Campylobacter isolate was submitted each week from 
participating FoodNet sites.  
 
Testing of Salmonella, Shigella, and Escherichia coli O157  
  
Antimicrobial Susceptibility Testing 
 
Salmonella, Shigella, and E. coli O157 isolates were tested using broth microdilution (Sensititre®, Trek 
Diagnostics, Cleveland, OH) to determine the minimum inhibitory concentration (MIC) for each of 15 antimicrobial 
agents: amikacin, ampicillin, amoxicillin-clavulanic acid, cefoxitin, ceftiofur, ceftriaxone, chloramphenicol, 
ciprofloxacin, gentamicin, kanamycin, nalidixic acid, streptomycin, sulfisoxazole, tetracycline, and trimethoprim-
sulfamethoxazole (Table IV). Before 2004, sulfamethoxazole was used instead of sulfisoxazole to represent the 
sulfonamides. Interpretive criteria defined by CLSI were used when available. The resistance breakpoint for 
amikacin, according to CLSI guidelines, is ≥64 μg/mL. In 2002 and 2003, a truncated broth microdilution series 
was used for amikacin testing (0.5-4 µg/mL).  For isolates that grew in all amikacin dilutions on the Sensititre
   
panel (MIC>4 μg/mL), ETest® (AB BIODISK, Solna, Sweden) was performed to determine amikacin MIC. The 
amikacin ETest® strip range of dilutions was 0.016-256 μg/mL. Since 2004, amikacin had a full range of dilutions 
(0.5-64 µg/mL) on the Sensititre panel (CMV1AGNF). 
 
22 
Table III: Antimicrobial agents used for susceptibility testing for Salmonella, Shigella, and Escherichia coli 
O157 isolates, NARMS, 2007 
CLSI class Antimicrobial Agent 
Antimicrobial Agent 
Concentration 
Range (μg/mL) 
MIC Interpretive Standard (µg/mL) 
Susceptible Intermediate Resistant 
Aminoglycosides 
Amikacin 0.5–64 ≤16 32 ≥64 
Gentamicin 0.25–16 ≤4 8 ≥16 
Kanamycin 8–64 ≤16 32 ≥64 
Streptomycin* 32–64 ≤32  ≥64 
β –lactam / β-lactamase 
inhibitor combinations Amoxicillin-clavulanic acid 1/0.5–32/16 ≤8/4 16/8 ≥32/16 
Cephems 
Cefoxitin 0.5–32 ≤8 16 ≥32 
Ceftiofur 0.12–8 ≤2 4 ≥8 
Ceftriaxone 0.25–64 ≤8 16–32 ≥64 
Cephalothin† 2–32 ≤8 16 ≥32 
Folate pathway inhibitors 
Sulfamethoxazole 16–512 ≤256  ≥512 
Sulfisoxazole 16–256 ≤256  ≥512 
Trimethoprim- 
sulfamethoxazole 0.12/2.38–4/76 ≤2/38  ≥4/76 
Penicillins Ampicillin 1–32 ≤8 16 ≥32 
Phenicols Chloramphenicol 2–32 ≤8 16 ≥32 
Quinolones 
Ciprofloxacin 0.015–4 ≤1 2 ≥4 
Nalidixic acid 0.5–32 ≤16  ≥32 
Tetracyclines Tetracycline 4–32 ≤4 8 ≥16 
 
*  No CLSI breakpoints; resistance breakpoint used in NARMS is ≥64 µg/mL. 
†  Cephalothin has not been tested since 2003, but was tested in earlier years for Salmonella, Shigella, and E. coli O157. 
‡  Sulfamethoxazole, which was tested during 1996–2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004. 
 
  
 
 
 
23
Additional Testing of Salmonella Strains 
 
Cephalosporin Retesting of Isolates from 1996-1998 
 
Review of Salmonella isolates tested in NARMS during 1996 to 1998 gave conflicting cephalosporin susceptibility 
results. In particular, some isolates previously reported in NARMS as ceftiofur-resistant exhibited a low 
ceftriaxone MIC and, in some cases, did not exhibit an elevated MIC to other β-lactams. Because these findings 
suggested that some previously reported results were inaccurate, we retested, using the 2003 NARMS Sensititre® 
plate, isolates of Salmonella tested in NARMS during 1996 to 1998 that exhibited an MIC ≥2 μg/mL to ceftiofur or 
ceftriaxone. The retest results have been included in the NARMS annual reports since 2003.  
 
Serotype Confirmation/Categorization 
 
Salmonella serotype reported by the submitting laboratory was accepted with few exceptions. Serotype was 
confirmed by CDC for isolates that underwent subsequent molecular analysis for publication.  Because of 
challenges associated with interpretation of tartrate fermentation assays, ability to ferment tartrate was confirmed 
for isolates reported as Salmonella ser. Paratyphi B by the submitting laboratory (serotype Paratyphi B is by 
definition unable to ferment L(+) tartrate). To distinguish Salmonella serotypes Paratyphi B and Paratyphi B var 
L(+) tartrate+ (formerly serotype Java), CDC performed Jordan’s tartrate test and/or Kauffmann’s tartrate test on 
all Salmonella ser. Paratyphi B isolates from 1996 to 2007 for which the tartrate result was not reported or was 
reported to be negative. Isolates negative for tartrate fermentation by both assays were categorized as serotype 
Paratyphi B. Isolates that were positive for tartrate fermentation by either assay were categorized as serotype 
Paratyphi B var L(+) tartrate+. Confirmation of other biochemical reactions or somatic and flagellar antigens was 
not performed at CDC.  
 
Because of increased submissions of Salmonella ser. I 4,[5],12:i:- noted in previous years, and recognition of the 
possibility that this serotype may have been underreported in previous years, isolates reported as serogroup B 
and tested in NARMS during 1996 to 2007 were reviewed for additional information; isolates that could be clearly 
identified as serogroup B, first-phase flagellar antigen “i”, second phase flagellar antigen absent were categorized 
in this report as Salmonella ser. I 4,[5],12:i:-. 
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Testing of Campylobacter 
 
Changes in testing methods in 2005 
 
Starting in 2005, there were three major changes in the methodology used for Campylobacter.  First, a 
surveillance scheme for selecting a representative sample of Campylobacter isolates for submission by FoodNet 
sites was implemented in 2005, which changed from a previous scheme that selected one Campylobacter isolate 
each week for submission during 1997 to 2004. Second, from 2005 through 2007, Campylobacter isolates were 
susceptibility tested using Sensititre® (Trek Diagnostics, Cleveland, OH); isolates had been tested by Etest® (AB 
BIODISK, Solna, Sweden) from 1997 through 2004.  Third, florfenicol replaced chloramphenicol as the phenicol 
subclass representative drug, and telithromycin was added to the NARMS panel of agents tested in 2005. 
 
 
Identification/Speciation and Antimicrobial Susceptibility Testing 
 
From 2005 through 2007, isolates were confirmed as Campylobacter by determination of typical morphology 
using dark-field microscopy, and reactivity to catalase and oxidase tests. Identification of C. jejuni was performed 
using the hippurate hydrolysis test. Hippurate-positive isolates were identified as C. jejuni. Hippurate-negative 
isolates were further characterized with polymerase chain reaction (PCR) assay with specific targets for C. jejuni 
(mapA or hipO gene) or C. coli-specific ceuE gene (Linton et al. 1997, Gonzales et al. 1997, Pruckler et al. 2006). 
he same methodology was used during 1997–2002. T   
Beginning in 2005, the broth microdilution methodology (Sensititre®,Trek Diagnostics, Cleveland, OH) 
was used to determine the MICs for nine antimicrobial agents: azithromycin, ciprofloxacin, clindamycin, 
erythromycin, florfenicol, gentamicin, nalidixic acid, telithromycin, and tetracycline (Table V). Florfenicol 
replaced chloramphenicol in the NARMS panel to represent the phenicol antimicrobial subclass.  Similar 
to the 2004 report, CLSI interpretive criteria for erythromycin, ciprofloxacin, and tetracycline (published in 
2006) and revised NARMS criteria for azithromycin were used for all years in this report. 
 
In annual reports 
published before 2004, these CLSI interpretive criteria were not available, and NARMS used resistance 
breakpoints for azithromycin and erythromycin that were lower than the new and revised breakpoints.
 
 In 
addition, revised NARMS interpretive criteria, adopted from the FDA-CVM arm of NARMS, have been 
used for clindamycin, gentamicin, and nalidixic acid since 2004.  From 1997 to 2004, Etest® (AB 
Biomerieux, Solna, Sweden) was used for susceptibility testing of Campylobacter isolates. 
In 2003 and 2004, putative Campylobacter isolates were identified as C. jejuni or C. coli using BAX® 
System PCR Assay according to the manufacturer's instructions (DuPont Qualicon, Wilmington, DE). 
Isolates not identified as C. jejuni or C. coli were further characterized by other PCR assays (Linton et al. 
1996) or were characterized by the CDC Campylobacter Reference Laboratory.  
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Table IV: Antimicrobial agents used for susceptibility testing of Campylobacter isolates, NARMS,  
1997–2007 
CLSI class Antimicrobial Agent 
Antimicrobial Agent
Concentration Range (µg/mL)
Breakpoints 
Susceptible Intermediate Resistant 
Aminoglycosides Gentamicin 0.12–32 0.016–256* ≤2 4 ≥8 
Ketolides Telithromycin† 0.015–8 ≤4 8 ≥16 
Lincosamides Clindamycin 0.03–16 0.016–256* ≤2 4 ≥8 
Macrolides 
Azithromycin 0.015–64 0.016–256* ≤2 4 ≥8 
Erythromycin 0.03–64 0.016–256* ≤8 16 ≥32 
Phenicols 
Chloramphenicol‡ 0.016–256* ≤8 16 ≥32 
Florfenicol§ 0.03–64 ≤4 N/A N/A 
Quinolones 
Ciprofloxacin 0.015–64 0.002–32* ≤1 2 ≥4 
Nalidixic acid 4–64 0.016–256* ≤16 32 ≥64 
Tetracyclines Tetracycline 0.06–64 0.016–256* ≤4 8 ≥16 
 
*  Etest dilution range used from 1997–2004. 
† Telithromycin added to NARMS panel in 2005. 
‡ Chloramphenicol, tested from 1997–2004, was replaced by florfenicol in 2005.  
§ Currently only a susceptible breakpoint (≤4 µg/mL) has been established.  In this report isolates with a MIC ≥8 µg/mL  
  are categorized as resistant. 
 
Retesting 
 
Known mechanisms of quinolone resistance in Campylobacter are expected to confer equivalent susceptibilities 
to nalidixic acid and ciprofloxacin. Similarly, known mechanisms of macrolide resistance are expected to confer 
equivalent susceptibilities to erythromycin and azithromycin. Confirmatory testing of isolates with conflicting 
results was performed by broth microdilution methods (Sensititre
®
, Trek Diagnostics, Cleveland, OH). Totals 
reported here reflect the retest results. 
 
Data Analysis 
 
For all pathogens, MICs were categorized as resistant, intermediate (if applicable), or susceptible. Analysis was 
restricted to the first isolate received (per genus under surveillance) per patient in the calendar year.  If two or 
more isolates were received for the same patient for Salmonella Typhi, the first blood isolate collected would be 
included in analysis.  If no blood isolates were submitted, the first isolate collected would be included in analysis.  
Where established, CLSI interpretive criteria were used; streptomycin resistance was defined as MIC ≥64 μg/mL 
(Table III). The 95% confidence intervals (CIs) for the percentage of resistant isolates are included in the MIC 
distribution tables. The 95% CIs were calculated using the Clopper-Pearson exact method.  
When describing results for several years, multidrug resistance for Salmonella, Shigella, and E. coli O157 
isolates was limited to the eight CLSI classes tested in all years from 1996 through 2007 represented by 15 
agents: amikacin, amoxicillin-clavulanic acid, ampicillin, cefoxitin, ceftiofur, ceftriaxone, chloramphenicol, 
ciprofloxacin, gentamicin, kanamycin, nalidixic acid, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline, 
and trimethoprim-sulfamethoxazole. When describing multidrug resistance for several years for Campylobacter 
isolates, multidrug resistance was limited to the five CLSI classes tested in all years from 1997 through 2007, 
represented by ciprofloxacin, chloramphenicol/florfenicol, clindamycin, erythromycin, nalidixic acid, and 
tetracycline.  
MIC Distribution Tables and Proportional Figures 
 
An explanation on “how to read a table,” showing the distribution of MICs for antimicrobial agents tested, which 
we refer to as “squashtogram”, has been provided to assist the reader with the different parts of each table 
(Figure 1.01).  Proportional figures visually display data from squashtograms for an immediate comparative 
summary of resistance in specific pathogens and serotypes. These figures are a categorical visual aid for the 
interpretation of MIC values. For most antimicrobial agents tested, three categories (susceptible, intermediate, 
and resistant) are used to interpret MICs. The proportion representing each category is shown in a horizontal 
proportional bar chart (Figure 1.02). 
 
 
Figure 2.01:  How to read a squashtogram 
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Amikacin 0.0 0.0 [0.0–0.2] 7.4 70.1 20.8 1.6 0.1
Gentamicin 0.1 2.1 [1.5–2.8] 53.5 41.4 2.8 0.1 0.1 0.9 1.2
Streptomycin N/A 10.4 [9.1–11.7] 89.6 4.4 6.0
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 4.2 3.3 [2.6–4.1] 84.8 4.9 0.4 2.5 4.2 0.6 2.7
Cephems Ceftiofur 0.0 3.2 [2.6–4.1] 0.3 0.8 27.5 66.7 1.4 0.1 3.1
Ceftriaxone 2.3 0.4 [0.2–0.8] 96.7 0.1 0.5 1.4 0.9 0.3 0.1
Penicillins Ampicillin 0.0 10.1 [8.9–11.5] 81.2 8.3 0.3 0.1 0.1 10.0
Quinolones Ciprof loxacin 0.0 0.1 [0.0–0.3] 92.9 4.4 0.2 1.3 0.8 0.3 0.1
Nalidixic acid N/A 2.2 [1.7–3.0] 0.1 0.2 34.4 61.9 0.9 0.2 2.2
Aminoglycosides Kanamycin < 0.1 2.8 [2.2–3.6] 96.8 0.2 < 0.1 0.2 2.6
Cephems Cefoxitin 0.7 3.0 [2.3–3.7] 0.2 8.8 70.2 15.8 1.3 0.7 0.9 2.1
Folate pathway inhibitors Sulfisoxazole N/A 12.3 [11.0–13.8] 19.0 53.1 15.0 0.5 0.1 12.3
Trimethoprim-sulfamethoxazole N/A 1.6 [1.1–2.2] 79.7 18.3 0.2 0.2 0.1 1.5
Phenicols Chloramphenicol 0.7 7.3 [6.2–8.5] 0.8 41.7 49.5 0.7 0.4 6.9
Tetracyclines Tetracycline 0.1 14.5 [13.0–16.0] 85.4 0.1 0.9 4.2 9.4
CLSI† Antimicrobial Class Antimicrobial Agent
II
Percent of all isolates w ith MIC (µg/mL)**% of isolates
Rank*
I
Critically important 
antimicrobial agents
Highly important 
antimicrobial agents
Percent with
Intermediate 
susceptibility
Percent 
resistant
95% confidence interval 
for percent resistant
Sum of percents = 
% susceptible
Sum of percents = 
% intermediate
Sum of percents = 
% resistant
Single line is upper limit of 
susceptibility / lower limit of 
intermediate susceptibility
Double line is upper limit of 
intermediate susceptibility / 
lower limit of full resistance 
MIC value
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Figure 2.02: Proportional chart, a categorical graph of a squashtogram 
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%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Amikacin 0.0 0.0 [0.0–0.2] 7.4 70.1 20.8 1.6 0.1
Gentamicin 0.1 2.1 [1.5–2.8] 53.5 41.4 2.8 0.1 0.1 0.9 1.2
Streptomycin N/A 10.4 [9.1–11.7] 89.6 4.4 6.0
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 4.2 3.3 [2.6–4.1] 84.8 4.9 0.4 2.5 4.2 0.6 2.7
Cephems Ceftiofur 0.0 3.2 [2.6–4.1] 0.3 0.8 27.5 66.7 1.4 0.1 3.1
Ceftriaxone 2.3 0.4 [0.2–0.8] 96.7 0.1 0.5 1.4 0.9 0.3 0.1
Penicillins Ampicillin 0.0 10.1 [8.9–11.5] 81.2 8.3 0.3 0.1 0.1 10.0
Quinolones Ciprofloxacin 0.0 0.1 [0.0–0.3] 92.9 4.4 0.2 1.3 0.8 0.3 0.1
Nalidixic acid N/A 2.2 [1.7–3.0] 0.1 0.2 34.4 61.9 0.9 0.2 2.2
Aminoglycosides Kanamycin < 0.1 2.8 [2.2–3.6] 96.8 0.2 < 0.1 0.2 2.6
Cephems Cefoxitin 0.7 3.0 [2.3–3.7] 0.2 8.8 70.2 15.8 1.3 0.7 0.9 2.1
Folate pathway inhibitors Sulfisoxazole N/A 12.3 [11.0–13.8] 19.0 53.1 15.0 0.5 0.1 12.3
Trimethoprim-sulfamethoxazole N/A 1.6 [1.1–2.2] 79.7 18.3 0.2 0.2 0.1 1.5
Phenicols Chloramphenicol 0.7 7.3 [6.2–8.5] 0.8 41.7 49.5 0.7 0.4 6.9
Tetracyclines Tetracycline 0.1 14.5 [13.0–16.0] 85.4 0.1 0.9 4.2 9.4
*
†
‡
§
¶
**
Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I):  Rank 1, Critically Important; Rank 2, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percent of isolates w ith intermediate susceptibility, N/A if no MIC range of intermediate susceptibility exists
Percent of isolates that w ere resistant
95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Clopper-Pearson exact method.  The 95% CI is presented to summarize uncertainly in the observed resistance (R%).
The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the low est tested concentrations represent the precentages of isolates w ith MICs equal to 
or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
Percent of all isolates w ith MIC (µg/mL)**% of isolates
CLSI† Antimicrobial Class Antimicrobial Agent
II
I
Rank*
 
Amikacin
Gentamicin
Streptomycin
Amoxicillin-clavulanic Acid
Ceftiofur
Ceftriaxone
Ampicillin
Ciprofloxacin
Nalidixic Acid
Kanamycin
Cefoxitin
Sulfisoxazole
Trimethoprim-sulfamethoxazole
Chloramphenicol
Tetracycline
Antimicrobial Agent Susceptible, Intermediate, and Resistant Proportion
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Results   
 
 
1. Non-typhoidal Salmonella  
 
Table 1.01: Minimum inhibitory concentrations (MICs) and resistance of non-typhoidal Salmonella isolates 
to antimicrobial agents, 2007 (N=2,144) 
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Amikacin 0.0 0.0 [0.0–0.2] 7.4 70.1 20.8 1.6 0.1
Gentamicin 0.1 2.1 [1.5–2.8] 53.5 41.4 2.8 0.1 0.1 0.9 1.2
Streptomycin N/A 10.4 [9.1–11.7] 89.6 4.4 6.0
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 4.2 3.3 [2.6–4.1] 84.8 4.9 0.4 2.5 4.2 0.6 2.7
Cephems Ceftiofur 0.0 3.2 [2.6–4.1] 0.3 0.8 27.5 66.7 1.4 0.1 3.1
Ceftriaxone 2.3 0.4 [0.2–0.8] 96.7 0.1 0.5 1.4 0.9 0.3 0.1
Penicillins Ampicillin 0.0 10.1 [8.9–11.5] 81.2 8.3 0.3 0.1 0.1 10.0
Quinolones Ciprofloxacin 0.0 0.1 [0.0–0.3] 92.9 4.4 0.2 1.3 0.8 0.3 0.1
Nalidixic acid N/A 2.2 [1.7–3.0] 0.1 0.2 34.4 61.9 0.9 0.2 2.2
Aminoglycosides Kanamycin < 0.1 2.8 [2.2–3.6] 96.8 0.2 < 0.1 0.2 2.6
Cephems Cefoxitin 0.7 3.0 [2.3–3.7] 0.2 8.8 70.2 15.8 1.3 0.7 0.9 2.1
Folate pathway inhibitors Sulfisoxazole N/A 12.3 [11.0–13.8] 19.0 53.1 15.0 0.5 0.1 12.3
Trimethoprim-sulfamethoxazole N/A 1.6 [1.1–2.2] 79.7 18.3 0.2 0.2 0.1 1.5
Phenicols Chloramphenicol 0.7 7.3 [6.2–8.5] 0.8 41.7 49.5 0.7 0.4 6.9
Tetracyclines Tetracycline 0.1 14.5 [13.0–16.0] 85.4 0.1 0.9 4.2 9.4
*
†
‡
§
¶
**
Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I):  Rank 1, Critically Important; Rank 2, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percent of isolates w ith intermediate susceptibility, N/A if no MIC range of intermediate susceptibility exists
Percent of isolates that w ere resistant
95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Clopper-Pearson exact method.  The 95% CI is presented to summarize uncertainly in the observed resistance (R%).
The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the low est tested concentrations represent the precentages of isolates w ith MICs equal to 
or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
Percent of all isolates w ith MIC (µg/mL)**% of isolates
CLSI† Antimicrobial Class Antimicrobial Agent
II
I
Rank*
  
 
Figure 2.03: Antimicrobial resistance pattern for non-typhoidal Salmonella, 2007 
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Table 1.02: Percentage and number of non-typhoidal Salmonella isolates resistant to antimicrobial 
agents, 1998–2007 
 
Year 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Total Isolates 1455 1493 1372 1410 1998 1855 1782 2034 2173 2144
CLSI† Antimicrobial
Class
Antibiotic
(Resistance breakpoint)
Aminoglycosides Amikacin 0.0% 0.1% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) 0 1 0 0 0 0 0 1 0 0
Gentamicin 2.8% 2.1% 2.7% 1.9% 1.4% 1.4% 1.3% 2.2% 2.0% 2.1%
(MIC ≥ 16) 41 32 37 27 27 26 24 44 44 45
Streptomycin 18.7% 16.7% 16.3% 17.1% 13.2% 15.0% 11.9% 11.1% 10.7% 10.4%
(MIC ≥ 64) 272 250 223 241 264 279 212 225 233 222
Amoxicillin-clavulanic acid 1.7% 2.3% 3.9% 4.7% 5.3% 4.6% 3.8% 3.2% 3.7% 3.3%
(MIC ≥ 32/16) 25 34 54 66 106 86 67 65 81 70
Cephems Ceftiofur 0.8% 2.0% 3.2% 4.1% 4.4% 4.5% 3.4% 2.9% 3.6% 3.3%
(MIC ≥ 8) 12 30 44 58 87 83 61 60 79 70
Ceftriaxone 0.0% 0.3% 0.0% 0.0% 0.2% 0.4% 0.6% 0.1% 0.2% 0.4%
(MIC ≥ 64) 0 5 0 0 4 8 10 3 4 9
Penicillins Ampicillin 16.6% 15.5% 15.9% 17.5% 13.0% 13.6% 12.1% 11.4% 11.0% 10.1%
(MIC ≥ 32) 241 232 218 247 259 253 216 232 238 217
Quinolones Ciprofloxacin 0.1% 0.1% 0.4% 0.2% 0.1% 0.2% 0.2% 0.0% 0.1% 0.1%
(MIC ≥ 4) 1 1 5 3 1 3 4 1 2 2
Nalidixic acid 1.3% 0.9% 2.3% 2.3% 1.6% 1.9% 2.2% 1.9% 2.4% 2.2%
(MIC ≥ 32) 19 14 32 32 32 36 39 38 52 48
Aminoglycosides Kanamycin 5.7% 4.4% 5.6% 4.8% 3.8% 3.5% 2.8% 3.4% 2.9% 2.8%
(MIC ≥ 64) 83 65 77 68 76 64 50 70 63 61
Cephems Cefoxitin Not Not 3.2% 3.4% 4.3% 4.3% 3.5% 3.0% 3.5% 2.9%
(MIC ≥ 32) Tested Tested 44 48 86 79 62 62 77 63
Cephalothin 2.3% 3.5% 4.0% 4.0% 5.1% 5.3% Not Not Not Not
(MIC ≥ 32) 33 53 55 57 101 99 Tested Tested Tested Tested
Folate pathway inhibitors Sulfamethoxazole/Sulfisoxazole‡ 19.5% 18.0% 17.1% 17.8% 12.9% 15.1% 13.2% 12.6% 12.1% 12.3%
(MIC ≥ 512) 283 269 234 251 258 280 236 256 263 264
Trimethoprim-sulfamethoxazole 2.3% 2.0% 2.0% 2.0% 1.4% 1.9% 1.7% 1.7% 1.7% 1.5%
(MIC ≥ 4/76) 34 30 28 28 28 36 31 34 36 33
Phenicols Chloramphenicol 10.0% 9.2% 10.1% 11.6% 8.6% 10.1% 7.6% 7.8% 6.4% 7.3%
(MIC ≥ 32) 145 137 138 164 172 187 135 159 139 156
Tetracyclines Tetracycline 20.3% 19.4% 18.7% 19.9% 14.9% 16.3% 13.5% 13.9% 13.5% 14.5%
(MIC ≥ 16) 295 289 256 280 298 303 241 282 293 310
*
†
‡
β-lactam/β-lactamase inhibitor 
combinations
II
I
Rank*
Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I):  Rank 1, Critically Important; Rank 2, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Sulfamethoxazole, which was tested during 1996-2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004.
 
 
Table 1.03: Resistance patterns of non-typhoidal Salmonella isolates, 1998–2007 
  
1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
1455 1493 1372 1410 1998 1855 1782 2034 2173 2144
% % % % % % % % % %
n n n n n n n n n n
72.9% 74.1% 74.5% 72.5% 79.1% 78.0% 80.0% 80.9% 80.5% 81.1%
1060 1107 1022 1022 1580 1447 1425 1646 1749 1738
27.1% 25.9% 25.5% 27.5% 20.9% 22.0% 20.0% 19.1% 19.5% 18.9%
395 386 350 388 418 408 357 388 424 406
22.5% 20.2% 20.0% 22.1% 15.8% 17.5% 15.0% 14.8% 14.6% 14.2%
327 302 275 311 315 325 267 302 318 305
16.3% 14.7% 15.5% 16.7% 12.3% 14.2% 11.4% 12.0% 11.8% 11.1%
237 220 213 236 245 263 204 244 256 239
12.8% 11.9% 12.7% 13.5% 9.8% 11.4% 9.2% 9.1% 8.1% 8.2%
186 177 174 191 195 211 164 185 177 176
9.8% 8.5% 9.5% 10.3% 8.2% 9.8% 7.9% 7.2% 6.3% 6.9%
142 127 131 145 164 182 141 146 137 149
8.9% 8.4% 8.9% 10.1% 7.8% 9.3% 7.2% 6.9% 5.6% 6.3%
130 125 122 142 156 173 128 141 121 136
0.9% 0.9% 0.9% 0.5% 1.1% 1.2% 0.6% 0.9% 0.7% 0.7%
13 14 13 7 21 23 10 18 15 16
0.3% 1.5% 2.6% 2.6% 3.4% 3.2% 2.4% 2.0% 2.0% 2.1%
5 23 36 36 67 60 42 41 43 46
0.0% 0.1% 0.1% 0.1% 0.2% 0.1% 0.1% 0.1% 0.1% 0.2%
0 1 1 2 4 2 2 2 3 5
*
†
‡
§
CLSI: Clinical and Laboratory Standards Institute
ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole
ACSSuTAuCf: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftiofur 
Resistance ≥ 4 CLSI classes*
Resistance ≥ 2 CLSI classes*
No resistance detected 
At least ACSSuTAuCf§
At least ACSSuT† 
Total Isolates
Year
At least ceftiofur and nalidixic acid resistant
At least ACT/S‡
Resistance ≥ 5 CLSI classes*
Resistance ≥ 3 CLSI classes*
Resistance ≥ 1 CLSI class*
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Table 1.04: Twenty most common non-typhoidal Salmonella serotypes in NARMS and the Public Health 
Laboratory Information System (PHLIS), 2007 
 
Rank Serotype n (%) Rank Serotype n (%)
1 Typhimurium 403 (18.8%) 1 Typhimurium 5459 (15.6%)
2 Enteritidis 385 (18.0%) 2 Enteritidis 5333 (15.3%)
3 Newport 220 (10.3%) 3 Newport 3119 (8.9%)
4 Heidelberg 98 (4.6%) 4 Heidelberg 1384 (4.0%)
5 I 4,[5],12:i:- 73 (3.4%) 5 Javiana 1118 (3.2%)
6 Javiana 65 (3.0%) 6 I 4,[5],12:i:- 1004 (2.9%)
7 Muenchen 64 (3.0%) 7 Muenchen 871 (2.5%)
8 Montevideo 51 (2.4%) 8 Montevideo 843 (2.4%)
9 Tennessee 38 (1.8%) 9 Tennessee 625 (1.8%)
10 Mississippi 37 (1.7%) 10 Oranienburg 588 (1.7%)
11 Oranienburg 37 (1.7%) 11 Braenderup 493 (1.4%)
12 Braenderup 36 (1.7%) 12 Infantis 469 (1.3%)
13 Agona 32 (1.5%) 13 Saintpaul 435 (1.2%)
14 Saintpaul 32 (1.5%) 14 Agona 433 (1.2%)
15 Infantis 26 (1.2%) 15 Mississippi 430 (1.2%)
16 Paratyphi B var. L(+) tartrate+ 25 (1.2%) 16 Thompson 364 (1.0%)
17 Mbandaka 24 (1.1%) 17 Paratyphi B var. L(+) tartrate+ 322 (0.9%)
18 Poona 22 (1.0%) 18 Schwarzengrund 277 (0.9%)
19 Stanley 20 (0.9%) 19 Hadar 248 (0.8%)
20 Schwarzengrund 19 (0.9%) 20 Bareilly 227 (0.7%)
Subtotal 1707 (79.6%) Subtotal 24042 (68.9%)
All other serotypes 383 (17.9%) All other serotypes 5298 (15.2%)
Unknown serotype 13 (0.6%) Unknown serotype 4246 (12.2%)
Partially serotyped 24 (1.1%) Partially serotyped 1230 (3.5%)
Rough/Nonmotile isolates 17 (0.8%) Rough/Nonmotile isolates 84 (0.2%)
Subtotal 437 (20.4%) Subtotal 10858 (31.1%)
Grand Total 2144 (100.0%) Grand Total 34900 (100.0%)
NARMS
Isolates
PHLIS
Isolates
 
 
A. Salmonella ser. Enteritidis 
 
Table 1.05: Minimum inhibitory concentrations (MICs) and resistance of Salmonella ser. Enteritidis 
isolates to antimicrobial agents, 2007 (N=385) 
 
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Amikacin 0.0 0.0 [0.0–1.0] 20.3 70.6 8.1 1.0
Gentamicin 0.0 0.0 [0.0–1.0] 78.4 20.3 1.0 0.3
Streptomycin N/A 0.6 [0.1–1.9] 99.5 0.3 0.3
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 0.0 0.5 [0.1–1.9] 89.4 8.6 0.3 1.3 0.5
Cephems Ceftiofur 0.0 0.3 [0.0–1.4] 0.3 0.3 8.6 88.8 1.8 0.3
Ceftriaxone 0.3 0.0 [0.0–1.0] 99.7 0.3
Penicillins Ampicillin 0.0 2.1 [0.9–4.1] 76.6 20.8 0.3 0.3 2.1
Quinolones Ciprofloxacin 0.0 0.0 [0.0–1.0] 80.8 13.2 4.4 1.6
Nalidixic acid N/A 5.7 [3.6–8.5] 0.3 15.6 77.1 1.0 0.3 5.7
Aminoglycosides Kanamycin 0.0 0.5 [0.1–1.9] 99.5 0.5
Cephems Cefoxitin 0.3 0.3 [0.0–1.4] 0.3 7.5 85.7 4.4 1.6 0.3 0.3
Folate pathway inhibitors Sulfisoxazole N/A 1.6 [0.6–3.4] 17.9 64.4 15.3 0.8 1.6
Trimethoprim-sulfamethoxazole N/A 1.0 [0.3–2.6] 83.9 14.0 0.5 0.5 1.0
Phenicols Chloramphenicol 0.8 0.6 [0.1–1.9] 1.0 51.2 46.5 0.8 0.3 0.3
Tetracyclines Tetracycline 0.3 3.9 [2.2–6.3] 95.8 0.3 0.3 3.6
*
†
‡
§
¶
**
Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I):  Rank 1, Critically Important; Rank 2, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percent of isolates w ith intermediate susceptibility, N/A if no MIC range of intermediate susceptibility exists
Percent of isolates that w ere resistant
95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Clopper-Pearson exact method.  The 95% CI is presented to summarize uncertainly in the observed resistance (R%).
The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the low est tested concentrations represent the precentages of isolates w ith MICs equal to 
or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
II
I
Rank*
% of isolates Percent of all isolates w ith MIC (µg/mL)**
CLSI† Antimicrobial Class Antimicrobial Agent
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Figure 2.04: Antimicrobial resistance pattern for Salmonella ser. Enteritidis, 2007 
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Table 1.06: Percentage and number of Salmonella ser. Enteritidis isolates resistant to antimicrobial 
agents, 1998–2007 
 
 
 
Year 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Total Isolates 244 269 319 277 337 257 271 384 413 385
CLSI† Antimicrobial
Class
Antibiotic
(Resistance breakpoint)
Aminoglycosides Amikacin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) 0 0 0 0 0 0 0 0 0 0
Gentamicin 0.4% 0.0% 0.3% 0.0% 0.3% 0.4% 0.4% 0.8% 0.2% 0.0%
(MIC ≥ 16) 1 0 1 0 1 1 1 3 1 0
Streptomycin 1.6% 2.2% 0.0% 1.4% 1.5% 1.2% 2.2% 1.0% 1.2% 0.5%
(MIC ≥ 64) 4 6 0 4 5 3 6 4 5 2
Amoxicillin-clavulanic acid 0.0% 0.4% 0.0% 1.4% 0.6% 0.0% 0.0% 0.8% 0.5% 0.5%
(MIC ≥ 32/16) 0 1 0 4 2 0 0 3 2 2
Cephems Ceftiofur 0.0% 0.4% 0.0% 2.2% 0.0% 0.0% 0.0% 0.5% 0.5% 0.3%
(MIC ≥ 8) 0 1 0 6 0 0 0 2 2 1
Ceftriaxone 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) 0 0 0 0 0 0 0 0 0 0
Penicillins Ampicillin 6.1% 10.8% 7.5% 8.7% 6.8% 2.3% 4.1% 2.9% 4.4% 2.1%
(MIC ≥ 32) 15 29 24 24 23 6 11 11 18 8
Quinolones Ciprofloxacin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 4) 0 0 0 0 0 0 0 0 0 0
Nalidixic acid 2.0% 2.2% 2.2% 4.3% 3.9% 4.7% 6.6% 4.7% 7.0% 5.7%
(MIC ≥ 32) 5 6 7 12 13 12 18 18 29 22
Aminoglycosides Kanamycin 0.4% 0.4% 0.3% 0.7% 0.3% 0.0% 0.7% 0.3% 0.2% 0.5%
(MIC ≥ 64) 1 1 1 2 1 0 2 1 1 2
Cephems Cefoxitin Not Not 0.0% 0.4% 0.0% 0.0% 0.0% 1.0% 0.5% 0.3%
(MIC ≥ 32) Tested Tested 0 1 0 0 0 4 2 1
Cephalothin 0.0% 1.9% 0.9% 1.1% 0.6% 1.2% Not Not Not Not
(MIC ≥ 32) 0 5 3 3 2 3 Tested Tested Tested Tested
Folate pathway inhibitors Sulfamethoxazole/Sulfisoxazole‡ 2.0% 3.0% 0.9% 2.2% 1.5% 1.2% 1.8% 1.6% 1.5% 1.6%
(MIC ≥ 512) 5 8 3 6 5 3 5 6 6 6
Trimethoprim-sulfamethoxazole 0.8% 0.7% 0.0% 0.7% 0.6% 0.8% 0.0% 0.5% 0.5% 1.0%
(MIC ≥ 4/76) 2 2 0 2 2 2 0 2 2 4
Phenicols Chloramphenicol 0.0% 0.4% 0.0% 0.0% 0.3% 0.4% 0.4% 0.5% 0.0% 0.5%
(MIC ≥ 32) 0 1 0 0 1 1 1 2 0 2
Tetracyclines Tetracycline 6.6% 8.2% 1.9% 1.8% 4.2% 1.6% 3.3% 2.3% 1.7% 3.9%
(MIC ≥ 16) 16 22 6 5 14 4 9 9 7 15
*
†
‡
I
Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I):  Rank 1, Critically Important; Rank 2, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Sulfamethoxazole, which was tested during 1996-2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004.
β-lactam/β-lactamase inhibitor 
combinations
Rank*
II
S I R
Table 1.07: Resistance patterns of Salmonella ser. Enteritidis isolates, 1998–2007 
 
 
1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
244 269 319 277 337 257 271 384 413 385
% % % % % % % % % %
n n n n n n n n n n
87.7% 83.6% 89.0% 86.6% 87.5% 91.8% 87.1% 91.4% 88.6% 90.4%
214 225 284 240 295 236 236 351 366 348
12.3% 16.4% 11.0% 13.4% 12.5% 8.2% 12.9% 8.6% 11.4% 9.6%
30 44 35 37 42 21 35 33 47 37
6.1% 8.6% 1.9% 4.7% 3.9% 2.3% 3.0% 3.6% 2.9% 3.4%
15 23 6 13 13 6 8 14 12 13
0.4% 1.1% 0.3% 2.9% 2.1% 0.4% 1.1% 1.6% 1.7% 1.0%
1 3 1 8 7 1 3 6 7 4
0.0% 0.4% 0.0% 1.1% 0.6% 0.4% 0.7% 1.0% 0.7% 0.3%
0 1 0 3 2 1 2 4 3 1
0.0% 0.4% 0.0% 0.4% 0.0% 0.4% 0.7% 0.5% 0.2% 0.3%
0 1 0 1 0 1 2 2 1 1
0.0% 0.4% 0.0% 0.0% 0.0% 0.4% 0.4% 0.5% 0.0% 0.3%
0 1 0 0 0 1 1 2 0 1
0.0% 0.4% 0.0% 0.0% 0.0% 0.4% 0.0% 0.0% 0.0% 0.0%
0 1 0 0 0 1 0 0 0 0
0.0% 0.4% 0.0% 0.0% 0.0% 0.0% 0.0% 0.3% 0.0% 0.3%
0 1 0 0 0 0 0 1 0 1
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.3% 0.0% 0.3%
0 0 0 0 0 0 0 1 0 1
*
†
‡
§
CLSI: Clinical and Laboratory Standards Institute
ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole
ACSSuTAuCf: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftiofur 
Resistance ≥ 2 CLSI classes*
No resistance detected 
Total Isolates
Year
At least ceftiofur and nalidixic acid resistant
At least ACT/S‡
Resistance ≥ 5 CLSI classes*
Resistance ≥ 3 CLSI classes*
Resistance ≥ 1 CLSI class*
At least ACSSuTAuCf§
At least ACSSuT† 
Resistance ≥ 4 CLSI classes*
B. Salmonella ser. Typhimurium 
 
Table 1.08: Minimum inhibitory concentrations (MICs) and resistance of Salmonella ser. Typhimurium 
isolates to antimicrobial agents, 2007 (N=403) 
 
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Amikacin 0.0 0.0 [0.0–0.9] 2.7 71.0 24.6 1.5 0.2
Gentamicin 0.2 2.5 [1.2–4.5] 40.9 53.3 3.0 0.2 1.0 1.5
Streptomycin N/A 32.3 [27.7–37.1] 67.7 17.4 14.9
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 20.1 6.4 [4.3–9.3] 63.3 5.2 0.2 4.7 20.1 0.7 5.7
Cephems Ceftiofur 0.0 6.2 [4.1–9.0] 0.5 0.2 18.1 74.2 0.7 0.2 6.0
Ceftriaxone 3.7 0.7 [0.2–2.2] 93.8 1.7 2.7 1.0 0.5 0.2
Penicillins Ampicillin 0.0 31.5 [27.0–36.3] 58.8 9.7 31.5
Quinolones Ciprofloxacin 0.0 0.0 [0.0–0.9] 96.5 1.5 0.5 0.5 1.0
Nalidixic acid N/A 1.5 [0.5–3.2] 38.0 59.3 0.7 0.5 1.5
Aminoglycosides Kanamycin 0.2 5.7 [3.7–8.4] 93.3 0.7 0.2 0.2 5.5
Cephems Cefoxitin 0.7 5.4 [3.5–8.1] 6.0 74.2 12.2 1.5 0.7 1.7 3.7
Folate pathway inhibitors Sulfisoxazole N/A 37.2 [32.5–42.1] 13.2 46.7 3.0 37.2
Trimethoprim-sulfamethoxazole N/A 2.2 [1.0–4.2] 66.0 31.0 0.7 2.2
Phenicols Chloramphenicol 0.2 25.3 [21.1–29.9] 0.2 35.2 39.0 0.2 0.5 24.8
Tetracyclines Tetracycline 0.0 36.7 [32.0–41.6] 63.3 4.2 15.1 17.4
*
†
‡
§
¶
**
Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I):  Rank 1, Critically Important; Rank 2, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percent of isolates w ith intermediate susceptibility, N/A if no MIC range of intermediate susceptibility exists
Percent of isolates that w ere resistant
95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Clopper-Pearson exact method.  The 95% CI is presented to summarize uncertainly in the observed resistance (R%).
The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the low est tested concentrations represent the precentages of isolates w ith MICs equal to 
or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
Rank*
I
II
% of isolates Percent of all isolates w ith MIC (µg/mL)**
CLSI† Antimicrobial Class Antimicrobial Agent
 
32 
Figure 2.05: Antimicrobial resistance pattern for Salmonella ser. Typhimurium, 2007   
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Table 1.09: Percentage and number of Salmonella ser. Typhimurium isolates resistant to antimicrobial 
agents, 1998–2007 
 
Year 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Total Isolates 381 363 304 325 394 408 382 438 409 403
CLSI† Antimicrobial
Class
Antibiotic
(Resistance breakpoint)
Aminoglycosides Amikacin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) 0 0 0 0 0 0 0 0 0 0
Gentamicin 3.7% 2.2% 2.6% 1.5% 2.3% 2.0% 2.1% 1.8% 2.7% 2.5%
(MIC ≥ 16) 14 8 8 5 9 8 8 8 11 10
Streptomycin 47.8% 43.3% 39.5% 40.0% 32.0% 35.5% 31.7% 28.1% 29.3% 32.3%
(MIC ≥ 64) 182 157 120 130 126 145 121 123 120 130
Amoxicillin-clavulanic acid 4.5% 2.8% 6.3% 6.2% 7.6% 5.6% 4.7% 3.2% 4.4% 6.5%
(MIC ≥ 32/16) 17 10 19 20 30 23 18 14 18 26
Cephems Ceftiofur 1.8% 1.9% 3.6% 3.1% 4.3% 4.9% 4.5% 2.5% 4.2% 6.2%
(MIC ≥ 8) 7 7 11 10 17 20 17 11 17 25
Ceftriaxone 0.0% 0.3% 0.0% 0.0% 0.3% 0.2% 0.8% 0.0% 0.2% 0.7%
(MIC ≥ 64) 0 1 0 0 1 1 3 0 1 3
Penicillins Ampicillin 45.7% 41.3% 42.1% 42.5% 33.8% 36.3% 31.9% 29.0% 28.1% 31.5%
(MIC ≥ 32) 174 150 128 138 133 148 122 127 115 127
Quinolones Ciprofloxacin 0.0% 0.0% 0.0% 0.3% 0.0% 0.0% 0.0% 0.0% 0.2% 0.0%
(MIC ≥ 4) 0 0 0 1 0 0 0 0 1 0
Nalidixic acid 0.5% 0.0% 1.3% 0.6% 1.3% 1.2% 0.5% 0.9% 0.7% 1.5%
(MIC ≥ 32) 2 0 4 2 5 5 2 4 3 6
Aminoglycosides Kanamycin 15.7% 12.9% 13.2% 8.3% 7.6% 7.1% 5.8% 5.7% 5.1% 5.7%
(MIC ≥ 64) 60 47 40 27 30 29 22 25 21 23
Cephems Cefoxitin Not Not 3.6% 3.1% 4.3% 4.4% 4.7% 2.5% 3.9% 5.5%
(MIC ≥ 32) Tested Tested 11 10 17 18 18 11 16 22
Cephalothin 3.9% 4.4% 4.3% 3.1% 5.6% 6.1% Not Not Not Not
(MIC ≥ 32) 15 16 13 10 22 25 Tested Tested Tested Tested
Folate pathway inhibitors Sulfamethoxazole/Sulfisoxazole‡ 50.1% 45.7% 45.4% 43.1% 32.2% 38.7% 35.9% 32.0% 33.3% 37.2%
(MIC ≥ 512) 191 166 138 140 127 158 137 140 136 150
Trimethoprim-sulfamethoxazole 4.5% 2.8% 3.6% 2.5% 2.3% 3.4% 2.6% 2.7% 2.2% 2.2%
(MIC ≥ 4/76) 17 10 11 8 9 14 10 12 9 9
Phenicols Chloramphenicol 34.1% 28.9% 30.9% 31.7% 23.4% 28.2% 24.1% 24.4% 22.0% 25.3%
(MIC ≥ 32) 130 105 94 103 92 115 92 107 90 102
Tetracyclines Tetracycline 46.5% 41.9% 43.4% 43.4% 32.0% 38.2% 30.1% 30.4% 31.5% 36.7%
(MIC ≥ 16) 177 152 132 141 126 156 115 133 129 148
*
†
‡
II
I
Rank*
Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I):  Rank 1, Critically Important; Rank 2, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Sulfamethoxazole, which was tested during 1996-2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004.
β-lactam/β-lactamase inhibitor 
combinations
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Table 1.10: Resistance patterns of Salmonella ser. Typhimurium isolates, 1998–2007 
 
 
1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
381 363 304 325 394 408 382 438 409 403
% % % % % % % % % %
n n n n n n n n n n
46.5% 50.4% 49.3% 49.2% 59.9% 54.7% 60.7% 65.1% 62.6% 57.6%
177 183 150 160 236 223 232 285 256 232
53.5% 49.6% 50.7% 50.8% 40.1% 45.3% 39.3% 34.9% 37.4% 42.4%
204 180 154 165 158 185 150 153 153 171
51.2% 46.0% 46.4% 47.4% 36.3% 41.4% 36.9% 33.3% 34.0% 39.2%
195 167 141 154 143 169 141 146 139 158
46.7% 43.0% 43.4% 41.5% 32.5% 37.3% 31.4% 30.1% 30.3% 34.2%
178 156 132 135 128 152 120 132 124 138
43.3% 38.6% 39.8% 37.8% 28.4% 32.4% 27.5% 27.4% 26.9% 29.8%
165 140 121 123 112 132 105 120 110 120
34.1% 28.1% 29.6% 29.5% 23.1% 27.7% 24.1% 22.8% 20.8% 24.8%
130 102 90 96 91 113 92 100 85 100
32.5% 27.8% 28.0% 29.5% 21.6% 26.5% 23.3% 22.4% 19.6% 22.6%
124 101 85 96 85 108 89 98 80 91
2.6% 2.2% 1.6% 0.9% 2.0% 3.2% 1.6% 2.1% 0.7% 1.7%
10 8 5 3 8 13 6 9 3 7
1.0% 0.6% 2.0% 1.2% 1.8% 2.2% 2.6% 1.8% 2.9% 3.5%
4 2 6 4 7 9 10 8 12 14
0.0% 0.0% 0.3% 0.3% 0.5% 0.0% 0.0% 0.0% 0.0% 0.2%
0 0 1 1 2 0 0 0 0 1
*
†
‡
§
CLSI: Clinical and Laboratory Standards Institute
ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole
ACSSuTAuCf: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftiofur 
Resistance ≥ 2 CLSI classes*
No resistance detected 
Total Isolates
Year
At least ceftiofur and nalidixic acid resistant
At least ACT/S‡
Resistance ≥ 5 CLSI classes*
Resistance ≥ 3 CLSI classes*
Resistance ≥ 1 CLSI class*
At least ACSSuTAuCf§
At least ACSSuT† 
Resistance ≥ 4 CLSI classes*
 
C. Salmonella ser. Newport 
 
Table 1.11: Minimum inhibitory concentrations (MICs) and resistance of Salmonella ser. Newport isolates 
to antimicrobial agents, 2007 (N=220) 
 
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Amikacin 0.0 0.0 [0.0–1.7] 3.2 78.6 17.3 0.9
Gentamicin 0.0 1.0 [0.1–3.2] 49.5 46.8 2.7 0.5 0.5
Streptomycin N/A 10.0 [6.4–14.7] 90.0 0.5 9.5
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 0.0 7.8 [4.6–12.1] 86.4 3.6 2.3 2.3 5.5
Cephems Ceftiofur 0.0 7.7 [4.6–12.1] 0.5 0.5 32.3 59.1 7.7
Ceftriaxone 6.4 0.9 [0.1–3.2] 92.3 0.5 3.2 3.2 0.9
Penicillins Ampicillin 0.0 9.5 [6.0–14.2] 86.8 2.7 0.5 0.5 9.5
Quinolones Ciprofloxacin 0.0 0.0 [0.0–1.7] 98.6 1.4
Nalidixic acid N/A 0.0 [0.0–1.7] 0.9 33.6 65.5
Aminoglycosides Kanamycin 0.0 0.9 [0.1–3.2] 99.1 0.9
Cephems Cefoxitin 0.0 7.8 [4.6–12.1] 9.1 77.3 4.1 1.8 2.3 5.5
Folate pathway inhibitors Sulfisoxazole N/A 10.0 [6.4–14.7] 3.6 58.6 27.3 0.5 10.0
Trimethoprim-sulfamethoxazole N/A 1.9 [0.5–4.6] 78.6 19.5 0.5 1.4
Phenicols Chloramphenicol 0.0 9.1 [5.6–13.7] 1.4 65.9 23.6 0.5 8.6
Tetracyclines Tetracycline 0.0 9.6 [6.0–14.2] 90.5 1.4 8.2
*
†
‡
§
¶
**
I
II
Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I):  Rank 1, Critically Important; Rank 2, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percent of isolates w ith intermediate susceptibility, N/A if no MIC range of intermediate susceptibility exists
Percent of isolates that w ere resistant
95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Clopper-Pearson exact method.  The 95% CI is presented to summarize uncertainly in the observed resistance (R%).
The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the low est tested concentrations represent the precentages of isolates w ith MICs equal to 
or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
CLSI† Antimicrobial Class Antimicrobial Agent
% of isolates Percent of all isolates w ith MIC (µg/mL)**
Rank*
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Figure 2.06: Antimicrobial resistance pattern for Salmonella ser. Newport, 2007 
Amikacin
Gentamicin
Streptomycin
Amoxicillin-clavulanic Acid
Ceftiofur
Ceftriaxone
Ampicillin
Ciprofloxacin
Nalidixic Acid
Kanamycin
Cefoxitin
Sulfisoxazole
Trimethoprim-sulfamethoxazole
Chloramphenicol
Tetracycline
Antimicrobial Agent Susceptible, Intermediate, and Resistant Proportion
 
 
 
 S I R 
 
Table 1.12: Percentage and number of Salmonella ser. Newport isolates resistant to antimicrobial agents, 
1998–2007 
 
Year 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Total Isolates 77 99 121 124 241 223 191 207 217 220
CLSI† Antimicrobial
Class
Antibiotic
(Resistance breakpoint)
Aminoglycosides Amikacin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) 0 0 0 0 0 0 0 0 0 0
Gentamicin 0.0% 0.0% 2.5% 3.2% 3.3% 3.1% 0.5% 1.0% 0.9% 0.9%
(MIC ≥ 16) 0 0 3 4 8 7 1 2 2 2
Streptomycin 2.6% 19.2% 24.0% 31.5% 25.3% 24.2% 15.7% 14.0% 13.8% 10.0%
(MIC ≥ 64) 2 19 29 39 61 54 30 29 30 22
Amoxicillin-clavulanic acid 2.6% 18.2% 22.3% 26.6% 22.8% 21.5% 15.2% 12.6% 12.4% 7.7%
(MIC ≥ 32/16) 2 18 27 33 55 48 29 26 27 17
Cephems Ceftiofur 1.3% 18.2% 22.3% 27.4% 22.8% 22.0% 15.2% 12.6% 12.4% 7.7%
(MIC ≥ 8) 1 18 27 34 55 49 29 26 27 17
Ceftriaxone 0.0% 3.0% 0.0% 0.0% 0.8% 1.8% 2.6% 1.4% 0.5% 0.9%
(MIC ≥ 64) 0 3 0 0 2 4 5 3 1 2
Penicillins Ampicillin 2.6% 18.2% 23.1% 29.8% 24.9% 22.9% 15.7% 14.0% 15.2% 9.5%
(MIC ≥ 32) 2 18 28 37 60 51 30 29 33 21
Quinolones Ciprofloxacin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 4) 0 0 0 0 0 0 0 0 0 0
Nalidixic acid 0.0% 0.0% 0.8% 0.0% 0.8% 0.4% 0.5% 0.0% 0.5% 0.0%
(MIC ≥ 32) 0 0 1 0 2 1 1 0 1 0
Aminoglycosides Kanamycin 1.3% 1.0% 5.0% 7.3% 10.0% 4.5% 2.6% 1.9% 2.3% 0.9%
(MIC ≥ 64) 1 1 6 9 24 10 5 4 5 2
Cephems Cefoxitin Not Not 22.3% 25.8% 22.4% 21.5% 15.2% 12.6% 12.9% 7.7%
(MIC ≥ 32) Tested Tested 27 32 54 48 29 26 28 17
Cephalothin 2.6% 18.2% 22.3% 26.6% 22.8% 22.4% Not Not Not Not
(MIC ≥ 32) 2 18 27 33 55 50 Tested Tested Tested Tested
Folate pathway inhibitors Sulfamethoxazole/Sulfisoxazole‡ 3.9% 22.2% 23.1% 32.3% 25.7% 24.7% 16.8% 15.5% 15.2% 10.0%
(MIC ≥ 512) 3 22 28 40 62 55 32 32 33 22
Trimethoprim-sulfamethoxazole 1.3% 2.0% 4.1% 1.6% 4.1% 0.9% 2.1% 1.9% 3.2% 1.8%
(MIC ≥ 4/76) 1 2 5 2 10 2 4 4 7 4
Phenicols Chloramphenicol 2.6% 18.2% 23.1% 28.2% 25.3% 22.4% 15.2% 13.5% 12.4% 9.1%
(MIC ≥ 32) 2 18 28 35 61 50 29 28 27 20
Tetracyclines Tetracycline 2.6% 19.2% 23.1% 30.6% 25.7% 24.2% 16.8% 14.5% 14.3% 9.5%
(MIC ≥ 16) 2 19 28 38 62 54 32 30 31 21
*
†
‡
Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I):  Rank 1, Critically Important; Rank 2, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Sulfamethoxazole, which was tested during 1996-2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004.
β-lactam/β-lactamase inhibitor 
combinations
II
I
Rank*
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Table 1.13: Resistance patterns of Salmonella ser. Newport isolates, 1998–2007 
 
 
1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
77 99 121 124 241 223 191 207 217 220
% % % % % % % % % %
n n n n n n n n n n
94.8% 75.8% 75.2% 65.3% 72.2% 73.5% 82.2% 84.1% 82.9% 89.5%
73 75 91 81 174 164 157 174 180 197
5.2% 24.2% 24.8% 34.7% 27.8% 26.5% 17.8% 15.9% 17.1% 10.5%
4 24 30 43 67 59 34 33 37 23
2.6% 18.2% 23.1% 32.3% 25.3% 25.1% 17.3% 15.0% 16.1% 10.5%
2 18 28 40 61 56 33 31 35 23
2.6% 18.2% 23.1% 31.5% 25.3% 23.3% 16.2% 14.5% 15.2% 10.5%
2 18 28 39 61 52 31 30 33 23
2.6% 18.2% 23.1% 31.5% 25.3% 22.9% 15.7% 14.0% 13.4% 9.1%
2 18 28 39 61 51 30 29 29 20
2.6% 18.2% 23.1% 26.6% 23.7% 22.4% 14.7% 12.6% 12.9% 8.2%
2 18 28 33 57 50 28 26 28 18
1.3% 18.2% 23.1% 25.8% 23.7% 22.0% 14.7% 12.6% 12.0% 8.2%
1 18 28 32 57 49 28 26 26 18
1.3% 2.0% 4.1% 0.8% 3.7% 0.9% 1.0% 1.9% 2.3% 0.5%
1 2 5 1 9 2 2 4 5 1
1.3% 18.2% 22.3% 25.0% 22.8% 21.1% 14.7% 12.6% 10.6% 7.7%
1 18 27 31 55 47 28 26 23 17
0.0% 0.0% 0.0% 0.0% 0.4% 0.0% 0.5% 0.0% 0.0% 0.0%
0 0 0 0 1 0 1 0 0 0
*
†
‡
§
CLSI: Clinical and Laboratory Standards Institute
ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole
ACSSuTAuCf: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftiofur 
Resistance ≥ 2 CLSI classes*
No resistance detected 
Total Isolates
Year
At least ceftiofur and nalidixic acid resistant
At least ACT/S‡
Resistance ≥ 5 CLSI classes*
Resistance ≥ 3 CLSI classes*
Resistance ≥ 1 CLSI class*
At least ACSSuTAuCf§
At least ACSSuT† 
Resistance ≥ 4 CLSI classes*
D. Salmonella ser. I 4,[5],12:i:- 
 
Table 1.14: Minimum inhibitory concentrations (MICs) and resistance of Salmonella ser. I 4,[5],12:i:- 
isolates to antimicrobial agents, 2007 (N=73) 
 
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Amikacin 0.0 0.0 [0.0–4.9] 2.7 68.5 28.8
Gentamicin 0.0 1.4 [0.0–7.4] 38.4 57.5 2.7 1.4
Streptomycin N/A 8.2 [3.1–17.0] 91.8 5.5 2.7
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 1.4 1.4 [0.0–7.4] 94.5 2.7 1.4 1.4
Cephems Ceftiofur 0.0 2.7 [0.3–9.5] 32.9 63.0 1.4 2.7
Ceftriaxone 0.0 1.4 [0.0–7.4] 97.3 1.4 1.4
Penicillins Ampicillin 0.0 5.5 [1.5–13.4] 87.7 5.5 1.4 5.5
Quinolones Ciprofloxacin 0.0 0.0 [0.0–4.9] 94.5 4.1 1.4
Nalidixic acid N/A 1.4 [0.0–7.4] 61.6 37.0 1.4
Aminoglycosides Kanamycin 0.0 1.4 [0.0–7.4] 98.6 1.4
Cephems Cefoxitin 0.0 1.4 [0.0–7.4] 12.3 79.5 5.5 1.4 1.4
Folate pathway inhibitors Sulfisoxazole N/A 4.1 [0.9–11.5] 15.1 74.0 6.8 4.1
Trimethoprim-sulfamethoxazole N/A 1.4 [0.0–7.4] 91.8 6.8 1.4
Phenicols Chloramphenicol 0.0 1.4 [0.0–7.4] 65.8 32.9 1.4
Tetracyclines Tetracycline 0.0 9.6 [3.9–18.8] 90.4 1.4 1.4 6.8
*
†
‡
§
¶
**
I
II
Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I):  Rank 1, Critically Important; Rank 2, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percent of isolates w ith intermediate susceptibility, N/A if no MIC range of intermediate susceptibility exists
Percent of isolates that w ere resistant
95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Clopper-Pearson exact method.  The 95% CI is presented to summarize uncertainly in the observed resistance (R%).
The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the low est tested concentrations represent the precentages of isolates w ith MICs equal to 
or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
CLSI† Antimicrobial Class Antimicrobial Agent
% of isolates Percent of all isolates w ith MIC (µg/mL)**
Rank*
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Figure 2.07: Antimicrobial resistance pattern for Salmonella ser. I 4,[5],12:i:-, 2007 
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Table 1.15: Percentage and number of Salmonella ser. I 4,[5],12:i:- isolates resistant to antimicrobial 
agents, 1998–2007 
 
Year 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Total Isolates 0 8 13 14 35 37 36 33 105 73
CLSI† Antimicrobial
Class
Antibiotic
(Resistance breakpoint)
Aminoglycosides Amikacin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) 0 0 0 0 0 0 0 0 0
Gentamicin 0.0% 0.0% 7.1% 0.0% 5.4% 5.6% 0.0% 4.8% 1.4%
(MIC ≥ 16) 0 0 1 0 2 2 0 5 1
Streptomycin 0.0% 7.7% 14.3% 2.9% 8.1% 5.6% 3.0% 3.8% 8.2%
(MIC ≥ 64) 0 1 2 1 3 2 1 4 6
Amoxicillin-clavulanic acid 0.0% 0.0% 0.0% 2.9% 5.4% 2.8% 3.0% 3.8% 1.4%
(MIC ≥ 32/16) 0 0 0 1 2 1 1 4 1
Cephems Ceftiofur 0.0% 0.0% 7.1% 2.9% 5.4% 2.8% 3.0% 3.8% 2.7%
(MIC ≥ 8) 0 0 1 1 2 1 1 4 2
Ceftriaxone 0.0% 0.0% 0.0% 0.0% 0.0% 2.8% 0.0% 0.0% 1.4%
(MIC ≥ 64) 0 0 0 0 0 1 0 0 1
Penicillins Ampicillin 0.0% 7.7% 7.1% 8.6% 8.1% 5.6% 6.1% 6.7% 5.5%
(MIC ≥ 32) 0 1 1 3 3 2 2 7 4
Quinolones Ciprofloxacin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 4) 0 0 0 0 0 0 0 0 0
Nalidixic acid 0.0% 0.0% 0.0% 0.0% 2.7% 2.8% 0.0% 1.0% 1.4%
(MIC ≥ 32) 0 0 0 0 1 1 0 1 1
Aminoglycosides Kanamycin 0.0% 0.0% 7.1% 0.0% 0.0% 0.0% 0.0% 0.0% 1.4%
(MIC ≥ 64) 0 0 1 0 0 0 0 0 1
Cephems Cefoxitin Not Not 0.0% 2.9% 5.4% 2.8% 3.0% 3.8% 1.4%
(MIC ≥ 32) Tested Tested 0 1 2 1 1 4 1
Cephalothin 0.0% 0.0% 7.1% 2.9% 5.4% 0.0% Not Not Not
(MIC ≥ 32) 0 0 1 1 2 0 Tested Tested Tested
Folate pathway inhibitors Sulfamethoxazole/Sulfisoxazole‡ 12.5% 0.0% 14.3% 2.9% 5.4% 11.1% 0.0% 8.6% 4.1%
(MIC ≥ 512) 1 0 2 1 2 4 0 9 3
Trimethoprim-sulfamethoxazole 0.0% 0.0% 7.1% 2.9% 0.0% 2.8% 0.0% 0.0% 1.4%
(MIC ≥ 4/76) 0 0 1 1 0 1 0 0 1
Phenicols Chloramphenicol 0.0% 0.0% 7.1% 2.9% 0.0% 2.8% 0.0% 1.9% 1.4%
(MIC ≥ 32) 0 0 1 1 0 1 0 2 1
Tetracyclines Tetracycline 0.0% 7.7% 7.1% 5.7% 0.0% 11.1% 3.0% 8.6% 9.6%
(MIC ≥ 16) 0 1 1 2 0 4 1 9 7
*
†
‡
Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I):  Rank 1, Critically Important; Rank 2, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Sulfamethoxazole, which was tested during 1996-2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004.
β-lactam/β-lactamase inhibitor 
combinations
II
I
Rank*
 
 
 
Table 1.16: Resistance patterns of Salmonella ser. I 4,[5],12:i:- isolates, 1998–2007 
 
 
1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
0 8 13 14 35 37 36 33 105 73
% % % % % % % % %
n n n n n n n n n
87.5% 92.3% 78.6% 91.4% 78.4% 80.6% 87.9% 85.7% 82.2%
7 12 11 32 29 29 29 90 60
12.5% 7.7% 21.4% 8.6% 21.6% 19.4% 12.1% 14.3% 17.8%
1 1 3 3 8 7 4 15 13
0.0% 7.7% 14.3% 8.6% 10.8% 13.9% 3.0% 11.4% 6.8%
0 1 2 3 4 5 1 12 5
0.0% 7.7% 7.1% 5.7% 5.4% 8.3% 3.0% 9.5% 5.5%
0 1 1 2 2 3 1 10 4
0.0% 0.0% 7.1% 2.9% 0.0% 2.8% 0.0% 3.8% 2.7%
0 0 1 1 0 1 0 4 2
0.0% 0.0% 7.1% 2.9% 0.0% 2.8% 0.0% 2.9% 1.4%
0 0 1 1 0 1 0 3 1
0.0% 0.0% 7.1% 2.9% 0.0% 2.8% 0.0% 1.9% 1.4%
0 0 1 1 0 1 0 2 1
0.0% 0.0% 7.1% 2.9% 0.0% 0.0% 0.0% 0.0% 0.0%
0 0 1 1 0 0 0 0 0
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
0 0 0 0 0 0 0 0 0
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
0 0 0 0 0 0 0 0 0
*
†
‡
§
CLSI: Clinical and Laboratory Standards Institute
ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole
ACSSuTAuCf: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftiofur 
Resistance ≥ 2 CLSI classes*
No resistance detected 
Total Isolates
Year
At least ceftiofur and nalidixic acid resistant
At least ACT/S‡
Resistance ≥ 5 CLSI classes*
Resistance ≥ 3 CLSI classes*
Resistance ≥ 1 CLSI class*
At least ACSSuTAuCf§
At least ACSSuT† 
Resistance ≥ 4 CLSI classes*
 
 
E. Salmonella ser. Heidelberg 
 
Table 1.17: Minimum inhibitory concentrations (MICs) and resistance of Salmonella ser. Heidelberg 
isolates to antimicrobial agents, 2007 (N=98) 
 
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Amikacin 0.0 0.0 [0.0–3.7] 9.2 69.4 20.4 1.0
Gentamicin 2.0 16.3 [9.6–25.2] 55.1 24.5 2.0 2.0 9.2 7.1
Streptomycin N/A 12.2 [6.5–20.4] 87.8 6.1 6.1
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 3.1 7.1 [2.9–14.2] 79.6 2.0 8.2 3.1 2.0 5.1
Cephems Ceftiofur 0.0 7.1 [2.9–14.2] 42.9 49.0 1.0 7.1
Ceftriaxone 5.1 0.0 [0.0–3.7] 92.9 2.0 5.1
Penicillins Ampicillin 0.0 18.4 [11.3–27.5] 79.6 2.0 18.4
Quinolones Ciprofloxacin 0.0 0.0 [0.0–3.7] 96.9 3.1
Nalidixic acid N/A 0.0 [0.0–3.7] 13.3 86.7
Aminoglycosides Kanamycin 1.0 11.3 [5.7–19.2] 87.8 1.0 3.1 8.2
Cephems Cefoxitin 0.0 7.1 [2.9–14.2] 25.5 64.3 3.1 5.1 2.0
Folate pathway inhibitors Sulfisoxazole N/A 18.4 [11.3–27.5] 44.9 29.6 6.1 1.0 18.4
Trimethoprim-sulfamethoxazole N/A 0.0 [0.0–3.7] 84.7 15.3
Phenicols Chloramphenicol 1.0 3.1 [0.6–8.7] 26.5 69.4 1.0 3.1
Tetracyclines Tetracycline 0.0 22.5 [14.6–32.0] 77.6 4.1 18.4
*
†
‡
§
¶
**
I
II
Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I):  Rank 1, Critically Important; Rank 2, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percent of isolates w ith intermediate susceptibility, N/A if no MIC range of intermediate susceptibility exists
Percent of isolates that w ere resistant
95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Clopper-Pearson exact method.  The 95% CI is presented to summarize uncertainly in the observed resistance (R%).
The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the low est tested concentrations represent the precentages of isolates w ith MICs equal to 
or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
CLSI† Antimicrobial Class Antimicrobial Agent
% of isolates Percent of all isolates w ith MIC (µg/mL)**
Rank*
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Figure 2.08: Antimicrobial resistance pattern for Salmonella ser. Heidelberg, 2007 
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Table 1.18: Percentage and number of Salmonella ser. Heidelberg isolates resistant to antimicrobial 
agents, 1998–2007 
 
Year 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Total Isolates 101 88 79 102 105 96 93 125 102 98
CLSI† Antimicrobial
Class
Antibiotic
(Resistance breakpoint)
Aminoglycosides Amikacin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) 0 0 0 0 0 0 0 0 0 0
Gentamicin 16.8% 14.8% 8.9% 7.8% 3.8% 5.2% 4.3% 6.4% 4.9% 16.3%
(MIC ≥ 16) 17 13 7 8 4 5 4 8 5 16
Streptomycin 30.7% 23.9% 22.8% 25.5% 17.1% 12.5% 15.1% 13.6% 11.8% 12.2%
(MIC ≥ 64) 31 21 18 26 18 12 14 17 12 12
Amoxicillin-clavulanic acid 1.0% 1.1% 3.8% 2.9% 9.5% 5.2% 10.8% 8.8% 9.8% 7.1%
(MIC ≥ 32/16) 1 1 3 3 10 5 10 11 10 7
Cephems Ceftiofur 0.0% 0.0% 3.8% 2.9% 7.6% 5.2% 9.7% 8.8% 9.8% 7.1%
(MIC ≥ 8) 0 0 3 3 8 5 9 11 10 7
Ceftriaxone 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) 0 0 0 0 0 0 0 0 0 0
Penicillins Ampicillin 16.8% 6.8% 10.1% 9.8% 12.4% 10.4% 25.8% 20.0% 18.6% 18.4%
(MIC ≥ 32) 17 6 8 10 13 10 24 25 19 18
Quinolones Ciprofloxacin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 4) 0 0 0 0 0 0 0 0 0 0
Nalidixic acid 1.0% 1.1% 1.3% 0.0% 0.0% 1.0% 0.0% 0.8% 0.0% 0.0%
(MIC ≥ 32) 1 1 1 0 0 1 0 1 0 0
Aminoglycosides Kanamycin 12.9% 9.1% 15.2% 19.6% 10.5% 8.3% 8.6% 12.8% 8.8% 11.2%
(MIC ≥ 64) 13 8 12 20 11 8 8 16 9 11
Cephems Cefoxitin Not Not 2.5% 2.9% 8.6% 5.2% 8.6% 8.8% 8.8% 7.1%
(MIC ≥ 32) Tested Tested 2 3 9 5 8 11 9 7
Cephalothin 5.9% 3.4% 5.1% 3.9% 10.5% 7.3% Not Not Not Not
(MIC ≥ 32) 6 3 4 4 11 7 Tested Tested Tested Tested
Folate pathway inhibitors Sulfamethoxazole/Sulfisoxazole‡ 21.8% 18.2% 11.4% 8.8% 6.7% 7.3% 7.5% 8.0% 4.9% 18.4%
(MIC ≥ 512) 22 16 9 9 7 7 7 10 5 18
Trimethoprim-sulfamethoxazole 2.0% 1.1% 1.3% 2.0% 1.0% 2.1% 0.0% 0.8% 0.0% 0.0%
(MIC ≥ 4/76) 2 1 1 2 1 2 0 1 0 0
Phenicols Chloramphenicol 1.0% 1.1% 1.3% 1.0% 1.0% 0.0% 1.1% 0.8% 0.0% 3.1%
(MIC ≥ 32) 1 1 1 1 1 0 1 1 0 3
Tetracyclines Tetracycline 19.8% 18.2% 21.5% 24.5% 19.0% 16.7% 19.4% 18.4% 13.7% 22.4%
(MIC ≥ 16) 20 16 17 25 20 16 18 23 14 22
*
†
‡
II
I
Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I):  Rank 1, Critically Important; Rank 2, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Sulfamethoxazole, which was tested during 1996-2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004.
β-lactam/β-lactamase inhibitor 
combinations
Rank*
 
 
Table 1.19: Resistance patterns of Salmonella ser. Heidelberg isolates, 1998–2007 
 
 
1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
101 88 79 102 105 96 93 125 102 98
% % % % % % % % % %
n n n n n n n n n n
56.4% 68.2% 63.3% 64.7% 67.6% 68.8% 55.9% 62.4% 67.6% 58.2%
57 60 50 66 71 66 52 78 69 57
43.6% 31.8% 36.7% 35.3% 32.4% 31.3% 44.1% 37.6% 32.4% 41.8%
44 28 29 36 34 30 41 47 33 41
33.7% 26.1% 26.6% 28.4% 25.7% 17.7% 23.7% 24.8% 23.5% 28.6%
34 23 21 29 27 17 22 31 24 28
13.9% 10.2% 7.6% 7.8% 12.4% 10.4% 14.0% 15.2% 12.7% 17.3%
14 9 6 8 13 10 13 19 13 17
3.0% 3.4% 3.8% 2.0% 1.9% 0.0% 4.3% 4.8% 2.0% 5.1%
3 3 3 2 2 0 4 6 2 5
0.0% 0.0% 2.5% 1.0% 1.9% 0.0% 3.2% 1.6% 2.0% 4.1%
0 0 2 1 2 0 3 2 2 4
0.0% 0.0% 1.3% 1.0% 1.0% 0.0% 1.1% 0.0% 0.0% 3.1%
0 0 1 1 1 0 1 0 0 3
0.0% 0.0% 0.0% 0.0% 1.0% 0.0% 0.0% 0.0% 0.0% 0.0%
0 0 0 0 1 0 0 0 0 0
0.0% 0.0% 1.3% 1.0% 1.0% 0.0% 0.0% 0.0% 0.0% 0.0%
0 0 1 1 1 0 0 0 0 0
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
0 0 0 0 0 0 0 0 0 0
*
†
‡
§
CLSI: Clinical and Laboratory Standards Institute
ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole
ACSSuTAuCf: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftiofur 
Resistance ≥ 2 CLSI classes*
No resistance detected 
Total Isolates
Year
At least ceftiofur and nalidixic acid resistant
At least ACT/S‡
Resistance ≥ 5 CLSI classes*
Resistance ≥ 3 CLSI classes*
Resistance ≥ 1 CLSI class*
At least ACSSuTAuCf§
At least ACSSuT† 
Resistance ≥ 4 CLSI classes*
 
F. Specific Drug Resistance Phenotypes 
 
Table 1.20: Number and percentage of ACSSuT-, ACSSuTAuCf, Nalidixic Acid-, and Ceftiofur-resistant 
isolates among the 20 most common non-typhoidal Salmonella serotypes isolated in NARMS, 2007 
 
Rank Serotype N n (%) n (%) n (%) n (%)
1 Typhimurium 403 91 (66.9%) 14 (30.4%) 6 (12.5%) 25 (35.7%)
2 Enteritidis 385 1 (0.7%) 1 (2.2%) 22 (45.8%) 1 (1.4%)
3 Newport 220 18 (13.2%) 17 (37.0%) 0 (0.0%) 17 (24.3%)
4 Heidelberg 98 3 (2.2%) 0 (0.0%) 0 (0.0%) 7 (10.0%)
5 I 4,[5],12:i:- 73 1 (0.7%) 0 (0.0%) 1 (2.1%) 2 (2.9%)
6 Javiana 65 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
7 Muenchen 64 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
8 Montevideo 51 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
9 Tennessee 38 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
10 Mississippi 37 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
11 Oranienburg 37 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
12 Braenderup 36 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
13 Agona 32 7 (5.1%) 7 (15.2%) 1 (2.1%) 8 (11.4%)
14 Saintpaul 32 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (1.4%)
15 Infantis 26 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (1.4%)
16 Paratyphi B var. L(+) tartrate+ 25 2 (1.5%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
17 Mbandaka 24 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
18 Poona 22 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
19 Stanley 20 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
20 Schwarzengrund 19 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Subtotal 1707 123 (90.4%) 39 (84.8%) 30 (62.5%) 62 (88.6%)
All Other Serotypes 383 10 (7.4%) 5 (10.9%) 17 (35.4%) 6 (8.6%)
Unknown serotype 13 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Partially serotyped 24 3 (2.2%) 2 (4.3%) 0 (0.0%) 2 (2.9%)
Rough/Nonmotile isolates 17 0 (0.0%) 0 (0.0%) 1 (2.1%) 0 (0.0%)
Total 2144 136 (100.0%) 46 (100.0%) 48 (100.0%) 70 (100.0%)
*ACSSuT: ampicillin, chloramphenicol, streptomycin, sulfisoxazole, tetracycline
†ACSSuTAuCf = ACSSuT, amoxicillin-clavulanic acid, and ceftiofur
CeftiofurACSSuT* ACSSuTAuCf Nalidixic Acid
40 
2. Typhoidal Salmonella 
 
A. Salmonella ser. Typhi 
 
Table 2.01: Minimum inhibitory concentrations (MICs) and resistance of Salmonella ser. Typhi isolates to 
antimicrobial agents, 2007 (N=398) 
 
 
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Amikacin 0.0 0.0 [0.0–0.9] 29.9 65.6 4.3 0.3
Gentamicin 0.0 0.0 [0.0–0.9] 95.0 5.0
Streptomycin N/A 15.6 [12.2–19.5] 84.4 0.3 15.3
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 0.5 0.3 [0.0–1.4] 82.2 0.8 3.5 12.8 0.5 0.3
Cephems Ceftiofur 0.0 0.0 [0.0–0.9] 1.0 5.5 85.2 8.3
Ceftriaxone 0.0 0.0 [0.0–0.9] 99.7 0.3
Penicillins Ampicillin 0.0 17.1 [13.5–21.2] 82.7 0.3 17.1
Quinolones Ciprofloxacin 0.8 1.0 [0.3–2.6] 35.2 0.8 1.0 14.3 41.2 5.5 0.3 0.8 1.0
Nalidixic acid N/A 62.3 [57.3–67.1] 0.3 4.5 29.1 2.5 0.5 0.8 1.5 60.8
Aminoglycosides Kanamycin 0.0 0.0 [0.0–0.9] 100.0
Cephems Cefoxitin 0.8 0.5 [0.1–1.8] 4.0 34.4 9.0 44.5 6.8 0.8 0.5
Folate pathway inhibitors Sulfisoxazole N/A 17.6 [14.0–21.7] 61.6 17.8 2.5 0.3 0.3 17.6
Trimethoprim-sulfamethoxazole N/A 16.3 [12.8–20.3] 80.4 3.3 16.3
Phenicols Chloramphenicol 0.5 15.8 [12.4–19.8] 7.0 71.4 5.3 0.5 15.8
Tetracyclines Tetracycline 0.0 6.3 [4.1–9.1] 93.7 6.3
*
†
‡
§
¶
**
I
II
Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I):  Rank 1, Critically Important; Rank 2, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percent of isolates w ith intermediate susceptibility, N/A if no MIC range of intermediate susceptibility exists
Percent of isolates that w ere resistant
95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Clopper-Pearson exact method.  The 95% CI is presented to summarize uncertainly in the observed resistance (R%).
The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the low est tested concentrations represent the precentages of isolates w ith MICs equal to 
or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
% of isolates Percent of all isolates w ith MIC (µg/mL)**
CLSI† Antimicrobial Class Antimicrobial AgentRank*
 
 
Figure 3.01: Antimicrobial resistance pattern for Salmonella ser. Typhi, 2007 
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Table 2.02: Percentage and number of Salmonella ser. Typhi isolates resistant to antimicrobial agents, 
1999–2007
 
Year 1999 2000 2001 2002 2003 2004 2005 2006 2007
Total Isolates 167 177 197 195 334 304 318 322 398
CLSI† Antimicrobial
Class
Antibiotic
(Resistance breakpoint)
Aminoglycosides Amikacin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) 0 0 0 0 0 0 0 0 0
Gentamicin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 16) 0 0 0 0 0 0 0 0 0
Streptomycin 13.8% 9.0% 20.3% 7.2% 14.4% 11.8% 13.2% 18.9% 15.6%
(MIC ≥ 64) 23 16 40 14 48 36 42 61 62
Amoxicillin-clavulanic acid 0.6% 0.0% 0.0% 0.0% 0.3% 0.0% 0.0% 0.3% 0.3%
(MIC ≥ 32/16) 1 0 0 0 1 0 0 1 1
Cephems Ceftiofur 0.6% 0.0% 0.0% 0.0% 0.6% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 8) 1 0 0 0 2 0 0 0 0
Ceftriaxone 0.6% 0.0% 0.0% 0.0% 0.3% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) 1 0 0 0 1 0 0 0 0
Penicillins Ampicillin 13.2% 9.0% 20.3% 5.6% 16.2% 11.8% 13.2% 20.8% 17.1%
(MIC ≥ 32) 22 16 40 11 54 36 42 67 68
Quinolones Ciprofloxacin 0.0% 0.0% 0.0% 0.0% 0.3% 0.0% 0.3% 0.9% 1.0%
(MIC ≥ 4) 0 0 0 0 1 0 1 3 4
Nalidixic acid 19.2% 22.0% 29.9% 23.6% 37.7% 41.8% 48.4% 53.7% 62.3%
(MIC ≥ 32) 32 39 59 46 126 127 154 173 248
Aminoglycosides Kanamycin 0.0% 0.0% 0.5% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) 0 0 1 0 0 0 0 0 0
Cephems Cefoxitin Not 0.6% 0.5% 0.0% 0.9% 0.0% 0.0% 0.3% 0.5%
(MIC ≥ 32) Tested 1 1 0 3 0 0 1 2
Cephalothin 2.4% 1.1% 0.5% 1.5% 0.6% Not Not Not Not
(MIC ≥ 32) 4 2 1 3 2 Tested Tested Tested Tested
Folate pathway inhibitors Sulfamethoxazole/Sulfisoxazole‡ 16.8% 11.3% 20.8% 6.2% 17.1% 11.8% 14.2% 20.8% 17.6%
(MIC ≥ 512) 28 20 41 12 57 36 45 67 70
Trimethoprim-sulfamethoxazole 13.2% 9.0% 20.8% 6.7% 16.8% 13.2% 14.5% 20.8% 16.3%
(MIC ≥ 4/76) 22 16 41 13 56 40 46 67 65
Phenicols Chloramphenicol 12.6% 10.7% 20.8% 6.2% 16.5% 13.2% 13.2% 19.6% 15.8%
(MIC ≥ 32) 21 19 41 12 55 40 42 63 63
Tetracyclines Tetracycline 9.6% 9.6% 20.8% 6.7% 15.6% 8.9% 10.1% 8.4% 6.3%
(MIC ≥ 16) 16 17 41 13 52 27 32 27 25
*
†
‡
β-lactam/β-lactamase inhibitor 
combinations
Rank*
I
II
Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I):  Rank 1, Critically Important; Rank 2, Highly 
Important
CLSI: Clinical and Laboratory Standards Institute 
Sulfamethoxazole, which was tested during 1996-2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004.
Table 2.03: Resistance patterns of Salmonella ser. Typhi isolates, 1999–2007 
 
1999 2000 2001 2002 2003 2004 2005 2006 2007
167 177 197 195 334 304 318 324 398
% % % % % % % % %
n n n n n n n n n
71.3% 72.3% 58.9% 74.4% 56.3% 56.6% 48.1% 40.4% 35.4%
119 128 116 145 188 172 153 131 141
28.7% 27.7% 41.1% 25.6% 43.7% 43.4% 51.9% 59.6% 64.6%
48 49 81 50 146 132 165 193 257
15.0% 10.7% 22.8% 7.2% 18.0% 13.2% 14.5% 21.6% 18.1%
25 19 45 14 60 40 46 70 72
13.2% 9.6% 21.8% 6.7% 17.1% 12.8% 13.8% 20.7% 17.6%
22 17 43 13 57 39 44 67 70
13.2% 9.0% 21.3% 6.2% 16.5% 12.5% 12.9% 19.1% 17.1%
22 16 42 12 55 38 41 62 68
11.4% 7.9% 16.8% 5.6% 14.1% 11.8% 11.9% 16.7% 14.8%
19 14 33 11 47 36 38 54 59
9.6% 7.9% 16.8% 5.6% 12.6% 7.9% 9.1% 5.9% 3.8%
16 14 33 11 42 24 29 19 15
12.6% 9.0% 17.8% 5.6% 15.6% 11.8% 12.9% 18.5% 15.3%
21 16 35 11 52 36 41 60 61
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
0 0 0 0 0 0 0 0 0
0.0% 0.0% 0.0% 0.0% 0.3% 0.0% 0.0% 0.0% 0.0%
0 0 0 0 1 0 0 0 0
*
†
‡
§
Resistance ≥ 1 CLSI class*
At least ACSSuTAuCf§
At least ACSSuT† 
Resistance ≥ 4 CLSI classes*
Resistance ≥ 2 CLSI classes*
At least ACT/S‡
Resistance ≥ 5 CLSI classes*
Resistance ≥ 3 CLSI classes*
Year
CLSI: Clinical and Laboratory Standards Institute
ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole
ACSSuTAuCf: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftiofur 
Total Isolates
No resistance detected 
At least ceftiofur and nalidixic acid resistant
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B. Salmonella  ser. Paratyphi A, Paratyphi B, and Paratyphi C 
 
Table 2.04: Frequency of Salmonella ser. Paratyphi A, Paratyphi B, and Paratyphi C isolated in NARMS, 
2007 
 
 
N (%)
Paratyphi A 16 (94.1%)
Paratyphi B 1 (5.9%)
Paratyphi C 0 (0.0%)
Total 17 (100%)
2007Species
Table 2.05: Minimum inhibitory concentrations (MICs) and resistance of Salmonella ser. Paratyphi A, 
Paratyphi B, and Paratyphi C isolates to antimicrobial agents, 2007 (N=17) 
 
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Amikacin 0.0 0.0 [0.0–19.5] 94.1 5.9
Gentamicin 0.0 0.0 [0.0–19.5] 88.2 11.8
Streptomycin N/A 0.0 [0.0–19.5] 100.0
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 0.0 0.0 [0.0–19.5] 41.2 58.8
Cephems Ceftiofur 0.0 0.0 [0.0–19.5] 5.9 94.1
Ceftriaxone 0.0 0.0 [0.0–19.5] 100.0
Penicillins Ampicillin 0.0 0.0 [0.0–19.5] 100.0
Quinolones Ciprofloxacin 0.0 0.0 [0.0–19.5] 5.9 5.9 88.2
Nalidixic acid N/A 94.1 [71.3–99.9] 5.9 5.9 88.2
Aminoglycosides Kanamycin 0.0 0.0 [0.0–19.5] 100.0
Cephems Cefoxitin 0.0 0.0 [0.0–19.5] 82.4 17.6
Folate pathway inhibitors Sulfisoxazole N/A 0.0 [0.0–19.5] 41.2 47.1 11.8
Trimethoprim-sulfamethoxazole N/A 0.0 [0.0–19.5] 70.6 29.4
Phenicols Chloramphenicol 23.5 0.0 [0.0–19.5] 76.5 23.5
Tetracyclines Tetracycline 0.0 0.0 [0.0–19.5] 100.0
*
†
‡
§
¶
**
I
II
Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I):  Rank 1, Critically Important; Rank 2, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percent of isolates w ith intermediate susceptibility, N/A if no MIC range of intermediate susceptibility exists
Percent of isolates that w ere resistant
95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Clopper-Pearson exact method.  The 95% CI is presented to summarize uncertainly in the observed resistance (R%).
The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the low est tested concentrations represent the precentages of isolates w ith MICs equal to 
or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
% of isolates Percent of all isolates w ith MIC (µg/mL)**
CLSI† Antimicrobial Class Antimicrobial AgentRank*
 
 
Figure 3.02: Antimicrobial resistance pattern for Salmonella ser. Paratyphi A, Paratyphi B, and Paratyphi 
C, 2007 
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Table 2.06: Percentage and number of Salmonella ser. Paratyphi A, Paratyphi B, and Paratyphi C isolates 
resistant to antimicrobial agents, 1998–2007
 
Year 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Total Isolates 5 2 5 9 10 8 11 18 16 17
CLSI† Antimicrobial
Class
Antibiotic
(Resistance breakpoint)
Aminoglycosides Amikacin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) 0 0 0 0 0 0 0 0 0 0
Gentamicin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 16) 0 0 0 0 0 0 0 0 0 0
Streptomycin 0.0% 0.0% 20.0% 0.0% 10.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) 0 0 1 0 1 0 0 0 0 0
Amoxicillin-clavulanic acid 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 32/16) 0 0 0 0 0 0 0 0 0 0
Cephems Ceftiofur 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 8) 0 0 0 0 0 0 0 0 0 0
Ceftriaxone 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) 0 0 0 0 0 0 0 0 0 0
Penicillins Ampicillin 0.0% 0.0% 20.0% 0.0% 0.0% 12.5% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 32) 0 0 1 0 0 1 0 0 0 0
Quinolones Ciprofloxacin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 4) 0 0 0 0 0 0 0 0 0 0
Nalidixic acid 20.0% 0.0% 40.0% 55.6% 40.0% 75.0% 72.7% 66.7% 50.0% 94.1%
(MIC ≥ 32) 1 0 2 5 4 6 8 12 8 16
Aminoglycosides Kanamycin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) 0 0 0 0 0 0 0 0 0 0
Cephems Cefoxitin Not Not 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 32) Tested Tested 0 0 0 0 0 0 0 0
Cephalothin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% Not Not Not Not
(MIC ≥ 32) 0 0 0 0 0 0 Tested Tested Tested Tested
Folate pathway inhibitors Sulfamethoxazole/Sulfisoxazole‡ 0.0% 0.0% 20.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 512) 0 0 1 0 0 0 0 0 0 0
Trimethoprim-sulfamethoxazole 0.0% 0.0% 20.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 4/76) 0 0 1 0 0 0 0 0 0 0
Phenicols Chloramphenicol 0.0% 0.0% 20.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 32) 0 0 1 0 0 0 0 0 0 0
Tetracyclines Tetracycline 0.0% 0.0% 0.0% 0.0% 10.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 16) 0 0 0 0 1 0 0 0 0 0
*
†
‡
Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I):  Rank 1, Critically Important; Rank 2, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Sulfamethoxazole, which was tested during 1996-2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004.
β-lactam/β-lactamase inhibitor 
combinations
Rank*
I
II
 
Table 2.07: Resistance patterns of Salmonella ser. Paratyphi A, Paratyphi B, and Paratyphi C isolates, 
1998–2007 
 
 
1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
5 2 5 9 10 8 11 18 16 17
% % % % % % % % % %
n n n n n n n n n n
80.0% 100.0% 40.0% 44.4% 50.0% 12.5% 27.3% 33.3% 50.0% 5.9%
4 2 2 4 5 1 3 6 8 1
20.0% 0.0% 60.0% 55.6% 50.0% 87.5% 72.7% 66.7% 50.0% 94.1%
1 0 3 5 5 7 8 12 8 16
0.0% 0.0% 20.0% 0.0% 10.0% 0.0% 0.0% 0.0% 0.0% 0.0%
0 0 1 0 1 0 0 0 0 0
0.0% 0.0% 20.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
0 0 1 0 0 0 0 0 0 0
0.0% 0.0% 20.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
0 0 1 0 0 0 0 0 0 0
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
0 0 0 0 0 0 0 0 0 0
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
0 0 0 0 0 0 0 0 0 0
0.0% 0.0% 20.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
0 0 1 0 0 0 0 0 0 0
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
0 0 0 0 0 0 0 0 0 0
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
0 0 0 0 0 0 0 0 0 0
*
†
‡
§
CLSI: Clinical and Laboratory Standards Institute
ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole
ACSSuTAuCf: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftiofur 
Resistance ≥ 2 CLSI classes*
No resistance detected 
Total Isolates
Year
At least ceftiofur and nalidixic acid resistant
At least ACT/S‡
Resistance ≥ 5 CLSI classes*
Resistance ≥ 3 CLSI classes*
Resistance ≥ 1 CLSI class*
At least ACSSuTAuCf§
At least ACSSuT† 
Resistance ≥ 4 CLSI classes*
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3. Shigella 
 
Table 3.01: Frequency of Shigella species isolated in NARMS, 2007 
 
 
n (%)
Shigella sonnei 416 (86.3%)
Shigella flexneri 61 (12.7%)
Shigella boydii 4 (0.8%)
Other 1 (0.2%)
Total 482 (100.0%)
2007
Species
 
 
 
 
Table 3.02: Minimum inhibitory concentrations (MICs) and resistance of Shigella isolates to antimicrobial 
agents, 2007 (N=482) 
 
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Amikacin 0.0 0.0 [0.0–0.8] 1.7 3.1 38.6 52.5 4.1
Gentamicin 0.0 0.8 [0.2–2.1] 4.4 20.7 67.0 7.1 0.2 0.6
Streptomycin N/A 73.0 [68.8–76.9] 27.0 44.6 28.4
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 38.2 0.4 [0.1–1.5] 3.9 3.7 27.4 26.3 38.2 0.4
Cephems Ceftiofur 0.0 0.0 [0.0–0.8] 5.2 79.9 12.2 2.7
Ceftriaxone 0.0 0.0 [0.0–0.8] 99.4 0.4 0.2
Penicillins Ampicillin 1.0 63.5 [59.0–67.8] 6.8 23.4 4.6 0.6 1.0 0.4 63.1
Quinolones Ciprofloxacin 0.0 0.2 [0.0–1.2] 97.3 0.2 0.2 1.2 0.6 0.2 0.2
Nalidixic acid N/A 1.8 [0.9–3.5] 2.5 70.3 22.4 2.3 0.4 0.2 0.6 1.2
Aminoglycosides Kanamycin 0.0 0.2 [0.0–1.2] 99.4 0.4 0.2
Cephems Cefoxitin 0.2 0.0 [0.0–0.8] 0.2 4.8 74.7 19.5 0.6 0.2
Folate pathway inhibitors Sulfisoxazole N/A 25.7 [21.9–29.9] 68.5 4.6 0.8 0.4 25.7
Trimethoprim-sulfamethoxazole N/A 34.7 [30.4–39.1] 15.8 8.9 12.9 20.5 7.3 4.6 30.1
Phenicols Chloramphenicol 0.4 8.3 [6.0–11.1] 12.2 70.3 8.7 0.4 0.6 7.7
Tetracyclines Tetracycline 0.2 25.4 [21.7–29.7] 74.3 0.2 0.6 6.8 18.0
*
†
‡
§
¶
**
Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I):  Rank 1, Critically Important; Rank 2, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percent of isolates w ith intermediate susceptibility, N/A if no MIC range of intermediate susceptibility exists
Percent of isolates that w ere resistant
95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Clopper-Pearson exact method.  The 95% CI is presented to summarize uncertainly in the observed resistance (R%).
The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the low est tested concentrations represent the precentages of isolates w ith MICs equal to 
or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
% of isolates Percent of all isolates w ith MIC (µg/mL)**
CLSI† Antimicrobial Class Antimicrobial AgentRank*
I
II
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Figure 4.01: Antimicrobial resistance pattern for Shigella, 2007 
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Table 3.03: Percentage and number of Shigella isolates resistant to antimicrobial agents, 1999–2007 
 
Year 1999 2000 2001 2002 2003 2004 2005 2006 2007
Total Isolates 375 450 344 620 495 316 396 402 482
CLSI† Antimicrobial
Class
Antibiotic
(Resistance breakpoint)
Aminoglycosides Amikacin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) 0 0 0 0 0 0 0 0 0
Gentamicin 0.3% 0.2% 0.0% 0.2% 0.0% 0.0% 1.0% 0.2% 0.8%
(MIC ≥ 16) 1 1 0 1 0 0 4 1 4
Streptomycin 55.7% 57.1% 53.2% 54.4% 57.0% 60.8% 68.7% 60.7% 73.0%
(MIC ≥ 64) 209 257 183 337 282 192 272 244 352
Amoxicillin-clavulanic acid 1.1% 2.2% 4.4% 2.6% 1.4% 1.6% 1.0% 1.5% 0.4%
(MIC ≥ 32/16) 4 10 15 16 7 5 4 6 2
Cephems Ceftiofur 0.0% 0.0% 0.0% 0.2% 0.2% 0.3% 0.5% 0.2% 0.0%
(MIC ≥ 8) 0 0 0 1 1 1 2 1 0
Ceftriaxone 0.0% 0.0% 0.0% 0.0% 0.0% 0.3% 0.5% 0.0% 0.0%
(MIC ≥ 64) 0 0 0 0 0 1 2 0 0
Penicillins Ampicillin 77.6% 79.1% 79.7% 76.6% 79.4% 77.5% 70.7% 62.2% 63.5%
(MIC ≥ 32) 291 356 274 475 393 245 280 250 306
Quinolones Ciprofloxacin 0.0% 0.0% 0.3% 0.0% 0.0% 0.0% 0.0% 0.2% 0.2%
(MIC ≥ 4) 0 0 1 0 0 0 0 1 1
Nalidixic acid 1.6% 0.9% 1.7% 1.6% 1.0% 1.6% 1.5% 3.5% 1.9%
(MIC ≥ 32) 6 4 6 10 5 5 6 14 9
Aminoglycosides Kanamycin 0.5% 1.3% 0.6% 0.8% 0.4% 0.0% 0.8% 0.0% 0.2%
(MIC ≥ 64) 2 6 2 5 2 0 3 0 1
Cephems Cefoxitin Not 0.2% 1.2% 0.3% 0.0% 0.3% 0.3% 0.0% 0.0%
(MIC ≥ 32) Tested 1 4 2 0 1 1 0 0
Cephalothin 3.2% 8.0% 9.0% 6.6% 9.3% Not Not Not Not
(MIC ≥ 32) 12 36 31 41 46 Tested Tested Tested Tested
Folate pathway inhibitors Sulfamethoxazole/Sulfisoxazole‡ 56.0% 55.8% 56.4% 31.8% 33.9% 52.5% 57.6% 40.3% 25.7%
(MIC ≥ 512) 210 251 194 197 168 166 228 162 124
Trimethoprim-sulfamethoxazole 51.5% 52.9% 46.8% 37.3% 38.6% 51.6% 58.6% 58.2% 34.6%
(MIC ≥ 4/76) 193 238 161 231 191 163 232 234 167
Phenicols Chloramphenicol 17.3% 14.0% 21.5% 7.6% 8.5% 15.2% 10.9% 10.9% 8.3%
(MIC ≥ 32) 65 63 74 47 42 48 43 44 40
Tetracyclines Tetracycline 57.3% 44.9% 59.3% 30.6% 29.1% 49.4% 38.4% 34.6% 25.5%
(MIC ≥ 16) 215 202 204 190 144 156 152 139 123
*
†
‡
β-lactam/β-lactamase inhibitor 
combinations
Rank*
I
II
Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I):  Rank 1, Critically Important; Rank 2, Highly 
Important
CLSI: Clinical and Laboratory Standards Institute 
Sulfamethoxazole, which was tested during 1996-2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004.
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Table 3.04: Resistance patterns of Shigella isolates, 1999–2007 
 
 
1999 2000 2001 2002 2003 2004 2005 2006 2007
375 450 344 620 495 316 396 402 482
% % % % % % % % %
n n n n n n n n n
9.1% 7.3% 4.9% 8.2% 8.5% 4.4% 4.5% 5.2% 7.3%
34 33 17 51 42 14 18 21 35
90.9% 92.7% 95.1% 91.8% 91.5% 95.6% 95.5% 94.8% 92.7%
341 417 327 569 453 302 378 381 447
63.2% 64.7% 68.6% 55.2% 57.8% 66.8% 74.0% 70.6% 68.5%
237 291 236 342 286 211 293 284 330
59.7% 61.3% 60.2% 41.6% 40.2% 62.3% 61.4% 48.5% 33.2%
224 276 207 258 199 197 243 195 160
44.5% 31.8% 45.3% 24.4% 24.8% 32.9% 19.4% 15.4% 11.6%
167 143 156 151 123 104 77 62 56
9.9% 6.7% 8.4% 2.9% 3.6% 7.0% 4.8% 5.2% 4.6%
37 30 29 18 18 22 19 21 22
8.5% 5.6% 6.4% 1.8% 3.2% 6.0% 4.0% 5.0% 3.7%
32 25 22 11 16 19 16 20 18
9.9% 6.9% 7.0% 2.7% 3.6% 6.6% 6.3% 6.0% 3.9%
37 31 24 17 18 21 25 24 19
44.3% 44.4% 37.5% 29.8% 33.7% 37.7% 39.9% 34.1% 18.9%
166 200 129 185 167 119 158 137 91
0.3% 0.0% 0.6% 0.3% 0.8% 0.6% 0.5% 0.5% 0.8%
1 0 2 2 4 2 2 2 4
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
0 0 0 0 0 0 0 0 0
0.0% 0.0% 0.0% 0.0% 0.2% 0.3% 0.3% 0.2% 0.0%
0 0 0 0 1 1 1 1 0
*
†
‡
§
¶
**
Year
Total Isolates
CLSI: Clinical and Laboratory Standards Institute 
ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline 
ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole 
AT/S: resistance to ampicillin, trimethoprim-sulfamethoxazole
ANT/S: resistance to AT/S, naladixic acid
ACSSuTAuCf: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftiofur 
At least ceftiofur and nalidixic acid resistant
At least ANT/S¶
At least ACT/S‡
Resistance ≥ 5 CLSI classes*
At least ACSSuTAuCf**
At least AT/S§
At least ACSSuT† 
Resistance ≥ 4 CLSI classes*
Resistance ≥ 2 CLSI classes*
No resistance detected 
Resistance ≥ 3 CLSI classes*
Resistance ≥ 1 CLSI class*
Table 3.05: Minimum inhibitory concentrations (MICs) and resistance of Shigella sonnei isolates to 
antimicrobial agents, 2007 (N=416) 
 
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Amikacin 0.0 0.0 [0.0–0.9] 1.2 3.1 42.1 50.5 3.1
Gentamicin 0.0 0.9 [0.3–2.4] 3.4 21.4 67.3 7.0 0.2 0.7
Streptomycin N/A 76.4 [72.1–80.4] 23.6 50.0 26.4
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 36.3 0.5 [0.1–1.7] 3.4 1.4 29.6 28.8 36.3 0.5
Cephems Ceftiofur 0.0 0.0 [0.0–0.9] 2.9 82.2 12.7 2.2
Ceftriaxone 0.0 0.0 [0.0–0.9] 99.3 0.5 0.2
Penicillins Ampicillin 1.2 63.7 [58.9–68.3] 4.1 25.2 5.3 0.5 1.2 0.5 63.2
Quinolones Ciprofloxacin 0.0 0.0 [0.0–0.9] 98.1 0.2 1.2 0.5
Nalidixic acid N/A 1.5 [0.5–3.1] 2.6 73.3 20.0 2.4 0.2 0.5 1.0
Aminoglycosides Kanamycin 0.0 0.2 [0.0–1.3] 99.3 0.5 0.2
Cephems Cefoxitin 0.2 0.0 [0.0–0.9] 0.2 5.5 81.0 12.7 0.2 0.2
Folate pathway inhibitors Sulfisoxazole N/A 20.0 [16.2–24.1] 74.0 4.6 1.0 0.5 20.0
Trimethoprim-sulfamethoxazole N/A 32.2 [27.7–36.9] 13.9 7.5 14.2 23.8 8.4 5.3 26.9
Phenicols Chloramphenicol 0.5 1.2 [0.4–2.8] 9.1 79.6 9.6 0.5 1.2
Tetracyclines Tetracycline 0.2 16.1 [12.7–20.0] 83.7 0.2 0.7 7.5 7.9
*
†
‡
§
¶
**
Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I):  Rank 1, Critically Important; Rank 2, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percent of isolates w ith intermediate susceptibility, N/A if no MIC range of intermediate susceptibility exists
Percent of isolates that w ere resistant
95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Clopper-Pearson exact method.  The 95% CI is presented to summarize uncertainly in the observed resistance (R%).
The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the low est tested concentrations represent the precentages of isolates w ith MICs equal to 
or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
% of isolates Percent of all isolates w ith MIC (µg/mL)**
CLSI† Antimicrobial Class Antimicrobial AgentRank*
I
II
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Figure 4.02: Antimicrobial resistance pattern for Shigella sonnei, 2007 
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Table 3.06: Percentage and number of Shigella sonnei isolates resistant to antimicrobial agents, 1999–
2007 
 
Year 1999 2000 2001 2002 2003 2004 2005 2006 2007
Total Isolates 275 366 239 536 434 241 340 321 416
CLSI† Antimicrobial
Class
Antibiotic
(Resistance breakpoint)
Aminoglycosides Amikacin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) 0 0 0 0 0 0 0 0 0
Gentamicin 0.4% 0.3% 0.0% 0.0% 0.0% 0.0% 1.2% 0.0% 1.0%
(MIC ≥ 16) 1 1 0 0 0 0 4 0 4
Streptomycin 52.0% 56.0% 54.0% 55.4% 56.5% 58.1% 70.3% 61.7% 76.4%
(MIC ≥ 64) 143 205 129 297 245 140 239 198 318
Amoxicillin-clavulanic acid 0.4% 1.9% 4.6% 2.2% 1.4% 1.7% 1.2% 1.9% 0.5%
(MIC ≥ 32/16) 1 7 11 12 6 4 4 6 2
Cephems Ceftiofur 0.0% 0.0% 0.0% 0.0% 0.0% 0.4% 0.6% 0.0% 0.0%
(MIC ≥ 8) 0 0 0 0 0 1 2 0 0
Ceftriaxone 0.0% 0.0% 0.0% 0.0% 0.0% 0.4% 0.6% 0.0% 0.0%
(MIC ≥ 64) 0 0 0 0 0 1 2 0 0
Penicillins Ampicillin 79.6% 80.6% 82.8% 77.6% 79.7% 79.3% 70.6% 62.3% 63.7%
(MIC ≥ 32) 219 295 198 416 346 191 240 200 265
Quinolones Ciprofloxacin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 4) 0 0 0 0 0 0 0 0 0
Nalidixic acid 1.5% 1.1% 0.8% 1.5% 0.5% 1.7% 1.2% 2.8% 1.4%
(MIC ≥ 32) 4 4 2 8 2 4 4 9 6
Aminoglycosides Kanamycin 0.7% 1.6% 0.4% 0.4% 0.0% 0.0% 0.0% 0.0% 0.2%
(MIC ≥ 64) 2 6 1 2 0 0 0 0 1
Cephems Cefoxitin Not 0.3% 1.7% 0.4% 0.0% 0.4% 0.3% 0.0% 0.0%
(MIC ≥ 32) Tested 1 4 2 0 1 1 0 0
Cephalothin 2.9% 8.7% 12.6% 7.3% 10.1% Not Not Not Not
(MIC ≥ 32) 8 32 30 39 44 Tested Tested Tested Tested
Folate pathway inhibitors Sulfamethoxazole/Sulfisoxazole‡ 54.5% 56.0% 54.4% 29.9% 31.3% 49.0% 57.9% 33.3% 20.0%
(MIC ≥ 512) 150 205 130 160 136 118 197 107 83
Trimethoprim-sulfamethoxazole 53.1% 54.9% 50.6% 37.9% 38.5% 53.1% 61.2% 57.9% 32.2%
(MIC ≥ 4/76) 146 201 121 203 167 128 208 186 134
Phenicols Chloramphenicol 1.8% 2.7% 1.3% 0.2% 1.2% 2.5% 2.4% 0.9% 1.2%
(MIC ≥ 32) 5 10 3 1 5 6 8 3 5
Tetracyclines Tetracycline 46.2% 34.4% 44.8% 23.5% 22.1% 36.1% 29.4% 22.7% 16.1%
(MIC ≥ 16) 127 126 107 126 96 87 100 73 67
*
†
‡
Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I):  Rank 1, Critically Important; Rank 2, Highly 
Important
CLSI: Clinical and Laboratory Standards Institute 
Sulfamethoxazole, which was tested during 1996-2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004.
β-lactam/β-lactamase inhibitor 
combinations
Rank*
I
II
 
Table 3.07: Resistance patterns of Shigella sonnei isolates, 1999–2007 
 
 
1999 2000 2001 2002 2003 2004 2005 2006 2007
275 366 239 536 434 241 340 321 416
% % % % % % % % %
n n n n n n n n n
10.5% 7.7% 5.4% 7.1% 8.5% 5.0% 4.4% 4.7% 7.0%
29 28 13 38 37 12 15 15 29
89.5% 92.3% 94.6% 92.9% 91.5% 95.0% 95.6% 95.3% 93.0%
246 338 226 498 397 229 325 306 387
55.6% 60.7% 59.8% 51.9% 54.1% 59.8% 72.9% 67.3% 66.6%
153 222 143 278 235 144 248 216 277
53.1% 56.8% 51.9% 36.6% 35.3% 54.8% 58.5% 41.7% 27.6%
146 208 124 196 153 132 199 134 115
39.3% 25.4% 37.7% 19.8% 20.5% 25.7% 12.4% 8.1% 5.0%
108 93 90 106 89 62 42 26 21
0.7% 1.6% 1.3% 0.7% 0.5% 0.8% 0.9% 0.0% 1.2%
2 6 3 4 2 2 3 0 5
0.4% 0.8% 0.0% 0.0% 0.2% 0.0% 0.3% 0.0% 0.5%
1 3 0 0 1 0 1 0 2
1.8% 1.9% 0.8% 0.2% 0.9% 1.7% 2.4% 0.9% 0.5%
5 7 2 1 4 4 8 3 2
45.1% 46.2% 41.0% 30.2% 33.6% 39.4% 40.6% 32.1% 16.3%
124 169 98 162 146 95 138 103 68
0.0% 0.0% 0.0% 0.2% 0.2% 0.8% 0.3% 0.0% 0.7%
0 0 0 1 1 2 1 0 3
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
0 0 0 0 0 0 0 0 0
0.0% 0.0% 0.0% 0.0% 0.0% 0.4% 0.3% 0.0% 0.0%
0 0 0 0 0 1 1 0 0
*
†
‡
§
¶
**
Year
Total Isolates
CLSI: Clinical and Laboratory Standards Institute 
ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline 
ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole 
AT/S: resistance to ampicillin, trimethoprim-sulfamethoxazole
ANT/S: resistance to AT/S, naladixic acid
ACSSuTAuCf: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftiofur 
At least ceftiofur and nalidixic acid resistant
At least ANT/S¶
At least ACT/S‡
Resistance ≥ 5 CLSI classes*
At least ACSSuTAuCf**
At least AT/S§
At least ACSSuT† 
Resistance ≥ 4 CLSI classes*
Resistance ≥ 2 CLSI classes*
No resistance detected 
Resistance ≥ 3 CLSI classes*
Resistance ≥ 1 CLSI class*
Table 3:08: Minimum inhibitory concentrations and resistance of Shigella flexneri isolates to antimicrobial 
agents, 2007 (N=61) 
 
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Amikacin 0.0 0.0 [0.0–5.9] 4.9 3.3 16.4 63.9 11.5
Gentamicin 0.0 0.0 [0.0–5.9] 11.5 16.4 63.9 8.2
Streptomycin N/A 52.5 [39.3–65.4] 47.5 11.5 41.0
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 52.5 0.0 [0.0–5.9] 8.2 19.7 9.8 9.8 52.5
Cephems Ceftiofur 0.0 0.0 [0.0–5.9] 19.7 65.6 8.2 6.6
Ceftriaxone 0.0 0.0 [0.0–5.9] 100.0
Penicillins Ampicillin 0.0 63.9 [50.6–75.8] 26.2 8.2 1.6 63.9
Quinolones Ciprofloxacin 0.0 1.6 [0.0–8.8] 93.4 1.6 1.6 1.6 1.6
Nalidixic acid N/A 4.9 [1.0–13.7] 55.7 36.1 1.6 1.6 1.6 3.3
Aminoglycosides Kanamycin 0.0 0.0 [0.0–5.9] 100.0
Cephems Cefoxitin 0.0 0.0 [0.0–5.9] 32.8 63.9 3.3
Folate pathway inhibitors Sulfisoxazole N/A 62.3 [49.0–74.4] 32.8 4.9 62.3
Trimethoprim-sulfamethoxazole N/A 49.2 [36.1–62.3] 27.9 18.0 4.9 49.2
Phenicols Chloramphenicol 0.0 55.7 [42.4–68.5] 31.1 9.8 3.3 4.9 50.8
Tetracyclines Tetracycline 0.0 83.6 [71.9–91.8] 16.4 3.3 80.3
*
†
‡
§
¶
**
Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I):  Rank 1, Critically Important; Rank 2, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percent of isolates w ith intermediate susceptibility, N/A if no MIC range of intermediate susceptibility exists
Percent of isolates that w ere resistant
95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Clopper-Pearson exact method.  The 95% CI is presented to summarize uncertainly in the observed resistance (R%).
The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the low est tested concentrations represent the precentages of isolates w ith MICs equal to 
or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
% of isolates Percent of all isolates w ith MIC (µg/mL)**
CLSI† Antimicrobial Class Antimicrobial AgentRank*
I
II
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Figure 4.03: Antimicrobial resistance pattern for Shigella flexneri, 2007 
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Table 3.09: Percentage and number of Shigella flexneri isolates resistant to antimicrobial agents, 1999–
2007 
 
Year 1999 2000 2001 2002 2003 2004 2005 2006 2007
Total Isolates 87 75 91 73 51 62 52 74 61
CLSI† Antimicrobial
Class
Antibiotic
(Resistance breakpoint)
Aminoglycosides Amikacin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) 0 0 0 0 0 0 0 0 0
Gentamicin 0.0% 0.0% 0.0% 1.4% 0.0% 0.0% 0.0% 1.4% 0.0%
(MIC ≥ 16) 0 0 0 1 0 0 0 1 0
Streptomycin 63.2% 61.3% 47.3% 43.8% 60.8% 71.0% 57.7% 58.1% 52.5%
(MIC ≥ 64) 55 46 43 32 31 44 30 43 32
Amoxicillin-clavulanic acid 3.4% 4.0% 4.4% 5.5% 2.0% 1.6% 0.0% 0.0% 0.0%
(MIC ≥ 32/16) 3 3 4 4 1 1 0 0 0
Cephems Ceftiofur 0.0% 0.0% 0.0% 1.4% 2.0% 0.0% 0.0% 1.4% 0.0%
(MIC ≥ 8) 0 0 0 1 1 0 0 1 0
Ceftriaxone 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) 0 0 0 0 0 0 0 0 0
Penicillins Ampicillin 77.0% 77.3% 72.5% 75.3% 84.3% 80.6% 75.0% 63.5% 63.9%
(MIC ≥ 32) 67 58 66 55 43 50 39 47 39
Quinolones Ciprofloxacin 0.0% 0.0% 1.1% 0.0% 0.0% 0.0% 0.0% 1.4% 1.6%
(MIC ≥ 4) 0 0 1 0 0 0 0 1 1
Nalidixic acid 1.1% 0.0% 3.3% 2.7% 5.9% 1.6% 3.8% 5.4% 4.9%
(MIC ≥ 32) 1 0 3 2 3 1 2 4 3
Aminoglycosides Kanamycin 0.0% 0.0% 1.1% 4.1% 3.9% 0.0% 3.8% 0.0% 0.0%
(MIC ≥ 64) 0 0 1 3 2 0 2 0 0
Cephems Cefoxitin Not 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 32) Tested 0 0 0 0 0 0 0 0
Cephalothin 4.6% 2.7% 1.1% 2.7% 3.9% Not Not Not Not
(MIC ≥ 32) 4 2 1 2 2 Tested Tested Tested Tested
Folate pathway inhibitors Sulfamethoxazole/Sulfisoxazole‡ 58.6% 53.3% 57.1% 41.1% 52.9% 66.1% 55.8% 68.9% 62.3%
(MIC ≥ 512) 51 40 52 30 27 41 29 51 38
Trimethoprim-sulfamethoxazole 48.3% 42.7% 34.1% 28.8% 39.2% 46.8% 44.2% 59.5% 49.2%
(MIC ≥ 4/76) 42 32 31 21 20 29 23 44 30
Phenicols Chloramphenicol 64.4% 69.3% 74.7% 63.0% 68.6% 61.3% 65.4% 54.1% 55.7%
(MIC ≥ 32) 56 52 68 46 35 38 34 40 34
Tetracyclines Tetracycline 92.0% 92.0% 94.5% 78.1% 82.4% 95.2% 94.2% 83.8% 83.6%
(MIC ≥ 16) 80 69 86 57 42 59 49 62 51
*
†
‡
β-lactam/β-lactamase inhibitor 
combinations
Rank*
I
II
Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I):  Rank 1, Critically Important; Rank 2, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Sulfamethoxazole, which was tested during 1996-2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004.
 
Table 3.10: Resistance patterns of Shigella flexneri isolates, 1999–2007 
 
1999 2000 2001 2002 2003 2004 2005 2006 2007
87 75 91 73 51 62 52 74 61
% % % % % % % % %
n n n n n n n n n
4.6% 4.0% 3.3% 15.1% 7.8% 0.0% 5.8% 5.4% 9.8%
4 3 3 11 4 0 3 4 6
95.4% 96.0% 96.7% 84.9% 92.2% 100.0% 94.2% 94.6% 90.2%
83 72 88 62 47 62 49 70 55
83.9% 82.7% 89.0% 76.7% 86.3% 93.5% 80.8% 85.1% 80.3%
73 62 81 56 44 58 42 63 49
79.3% 81.3% 79.1% 75.3% 80.4% 90.3% 78.8% 75.7% 68.9%
69 61 72 55 41 56 41 56 42
63.2% 64.0% 62.6% 57.5% 62.7% 64.5% 65.4% 47.3% 55.7%
55 48 57 42 32 40 34 35 34
37.9% 32.0% 25.3% 19.2% 31.4% 29.0% 30.8% 28.4% 27.9%
33 24 23 14 16 18 16 21 17
33.3% 29.3% 22.0% 15.1% 29.4% 27.4% 28.8% 27.0% 26.2%
29 22 20 11 15 17 15 20 16
34.5% 32.0% 23.1% 21.9% 27.5% 24.2% 32.7% 28.4% 26.2%
30 24 21 16 14 15 17 21 16
44.8% 38.7% 25.3% 27.4% 37.3% 35.5% 38.5% 43.2% 36.1%
39 29 23 20 19 22 20 32 22
1.1% 0.0% 1.1% 1.4% 5.9% 0.0% 1.9% 2.7% 1.6%
1 0 1 1 3 0 1 2 1
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
0 0 0 0 0 0 0 0 0
0.0% 0.0% 0.0% 0.0% 2.0% 0.0% 0.0% 1.4% 0.0%
0 0 0 0 1 0 0 1 0
*
†
‡
§
¶
**
Year
Total Isolates
CLSI: Clinical and Laboratory Standards Institute 
ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline 
ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole 
AT/S: resistance to ampicillin, trimethoprim-sulfamethoxazole
ANT/S: resistance to AT/S, naladixic acid
ACSSuTAuCf: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftiofur 
At least ceftiofur and nalidixic acid resistant
At least ANT/S¶
At least ACT/S‡
Resistance ≥ 5 CLSI classes*
At least ACSSuTAuCf**
At least AT/S§
At least ACSSuT† 
Resistance ≥ 4 CLSI classes*
Resistance ≥ 2 CLSI classes*
No resistance detected 
Resistance ≥ 3 CLSI classes*
Resistance ≥ 1 CLSI class*
51 
4. Escherichia coli O157 
 
Table 4.01: Minimum inhibitory concentrations (MICs) and resistance of Escherichia coli O157 isolates to 
antimicrobial agents, 2007 (N=190) 
 
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Amikacin 0.0 0.0 [0.0–1.9] 2.6 65.3 30.0 1.6 0.5
Gentamicin 0.0 0.0 [0.0–1.9] 34.2 61.1 4.7
Streptomycin N/A 2.1 [0.6–5.3] 97.9 1.6 0.5
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 1.1 0.5 [0.0–2.9] 1.6 7.4 87.4 2.1 1.1 0.5
Cephems Ceftiofur 0.0 0.0 [0.0–1.9] 1.6 6.8 88.4 3.2
Ceftriaxone 0.0 0.0 [0.0–1.9] 100.0
Penicillins Ampicillin 0.0 2.1 [0.6–5.3] 5.3 70.5 22.1 2.1
Quinolones Ciprofloxacin 0.0 0.5 [0.0–2.9] 96.3 1.6 1.1 0.5 0.5
Nalidixic acid N/A 2.1 [0.6–5.3] 2.1 75.3 20.5 2.1
Aminoglycosides Kanamycin 0.0 0.0 [0.0–1.9] 100.0
Cephems Cefoxitin 3.2 0.0 [0.0–1.9] 2.1 3.2 67.4 24.2 3.2
Folate pathway inhibitors Sulfisoxazole N/A 2.6 [0.9–6.0] 88.4 7.9 0.5 0.5 2.6
Trimethoprim-sulfamethoxazole N/A 1.1 [0.1–3.8] 85.3 13.7 1.1
Phenicols Chloramphenicol 2.1 0.5 [0.0–2.9] 0.5 17.9 78.9 2.1 0.5
Tetracyclines Tetracycline 1.1 4.7 [2.2–8.8] 94.2 1.1 0.5 0.5 3.7
*
†
‡
§
¶
**
I
II
Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I):  Rank 1, Critically Important; Rank 2, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percent of isolates w ith intermediate susceptibility, N/A if no MIC range of intermediate susceptibility exists
Percent of isolates that w ere resistant
95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Clopper-Pearson exact method.  The 95% CI is presented to summarize uncertainly in the observed resistance (R%).
The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the low est tested concentrations represent the precentages of isolates w ith MICs equal to 
or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
% of isolates Percent of all isolates w ith MIC (µg/mL)**
CLSI† Antimicrobial Class Antimicrobial AgentRank*
 
 
Figure 5.01: Antimicrobial resistance pattern for Escherichia coli O157, 2007 
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Table 4.02: Percentage and number of Escherichia coli O157 isolates resistant to antimicrobial agents, 
1998–2007 
 
Year 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Total Isolates 318 292 407 277 399 158 169 194 233 190
CLSI† Antimicrobial
Class
Antibiotic
(Resistance breakpoint)
Aminoglycosides Amikacin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) 0 0 0 0 0 0 0 0 0 0
Gentamicin 0.0% 0.3% 0.5% 0.4% 0.0% 0.0% 0.6% 0.5% 0.0% 0.0%
(MIC ≥ 16) 0 1 2 1 0 0 1 1 0 0
Streptomycin 1.9% 2.7% 5.2% 1.8% 2.3% 1.9% 1.8% 2.1% 2.6% 2.1%
(MIC ≥ 64) 6 8 21 5 9 3 3 4 6 4
Amoxicillin-clavulanic acid 0.0% 0.3% 1.0% 0.7% 0.0% 1.3% 0.0% 0.0% 1.3% 0.5%
(MIC ≥ 32/16) 0 1 4 2 0 2 0 0 3 1
Cephems Ceftiofur 0.0% 0.0% 1.0% 1.1% 0.0% 1.3% 0.0% 0.0% 1.3% 0.0%
(MIC ≥ 8) 0 0 4 3 0 2 0 0 3 0
Ceftriaxone 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.9% 0.0%
(MIC ≥ 64) 0 0 0 0 0 0 0 0 2 0
Penicillins Ampicillin 2.5% 1.4% 2.7% 2.2% 1.5% 3.2% 1.2% 4.1% 2.6% 2.1%
(MIC ≥ 32) 8 4 11 6 6 5 2 8 6 4
Quinolones Ciprofloxacin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.4% 0.5%
(MIC ≥ 4) 0 0 0 0 0 0 0 0 1 1
Nalidixic acid 0.0% 0.7% 0.5% 1.1% 1.0% 0.6% 1.8% 1.5% 2.1% 2.1%
(MIC ≥ 32) 0 2 2 3 4 1 3 3 5 4
Aminoglycosides Kanamycin 0.3% 0.7% 1.0% 0.0% 0.5% 0.0% 0.0% 0.5% 0.4% 0.0%
(MIC ≥ 64) 1 2 4 0 2 0 0 1 1 0
Cephems Cefoxitin Not Not 1.0% 0.7% 0.0% 1.3% 0.6% 0.0% 1.3% 0.0%
(MIC ≥ 32) Tested Tested 4 2 0 2 1 0 3 0
Cephalothin 0.0% 0.7% 1.2% 1.4% 1.5% 3.2% Not Not Not Not
(MIC ≥ 32) 0 2 5 4 6 5 Tested Tested Tested Tested
Folate pathway inhibitors Sulfamethoxazole/Sulfisoxazole‡ 5.7% 8.2% 5.9% 5.1% 3.5% 3.8% 1.8% 6.7% 3.0% 2.6%
(MIC ≥ 512) 18 24 24 14 14 6 3 13 7 5
Trimethoprim-sulfamethoxazole 0.6% 1.4% 0.7% 0.7% 0.5% 0.6% 0.0% 0.5% 0.4% 1.1%
(MIC ≥ 4/76) 2 4 3 2 2 1 0 1 1 2
Phenicols Chloramphenicol 0.3% 0.0% 3.7% 1.4% 1.3% 1.3% 0.6% 1.0% 1.3% 0.5%
(MIC ≥ 32) 1 0 15 4 5 2 1 2 3 1
Tetracyclines Tetracycline 4.4% 3.4% 7.1% 5.4% 3.0% 5.7% 1.8% 8.8% 4.7% 4.7%
(MIC ≥ 16) 14 10 29 15 12 9 3 17 11 9
*
†
‡
β-lactam/β-lactamase inhibitor 
combinations
Rank*
I
II
Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I):  Rank 1, Critically Important; Rank 2, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Sulfamethoxazole, which was tested during 1996-2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004.
 
 
Table 4.03: Resistance patterns of Escherichia coli O157 isolates, 1998–2007 
 
  
1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
318 292 407 277 399 158 169 194 233 190
% % % % % % % % % %
n n n n n n n n n n
92.8% 89.7% 90.4% 91.3% 94.0% 90.5% 94.7% 87.6% 91.8% 92.1%
295 262 368 253 375 143 160 170 214 175
7.2% 10.3% 9.6% 8.7% 6.0% 9.5% 5.3% 12.4% 8.2% 7.9%
23 30 39 24 24 15 9 24 19 15
5.0% 3.4% 6.6% 5.4% 3.8% 5.1% 2.4% 6.7% 4.7% 3.2%
16 10 27 15 15 8 4 13 11 6
1.9% 2.7% 4.7% 2.2% 2.0% 3.2% 1.2% 5.2% 3.4% 2.1%
6 8 19 6 8 5 2 10 8 4
0.6% 0.7% 3.4% 1.4% 0.8% 1.3% 0.6% 1.0% 2.1% 1.1%
2 2 14 4 3 2 1 2 5 2
0.0% 0.0% 1.2% 0.4% 0.0% 0.0% 0.0% 0.0% 0.9% 0.5%
0 0 5 1 0 0 0 0 2 1
0.0% 0.0% 1.2% 0.4% 0.0% 0.0% 0.0% 0.0% 0.9% 0.0%
0 0 5 1 0 0 0 0 2 0
0.0% 0.0% 0.2% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
0 0 1 0 0 0 0 0 0 0
0.0% 0.0% 1.0% 0.4% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
0 0 4 1 0 0 0 0 0 0
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.4% 0.0%
0 0 0 0 0 0 0 0 1 0
*
†
‡
§
Total Isolates
At least ceftiofur and nalidixic acid resistant
At least ACT/S‡
Resistance ≥ 5 CLSI subclasses*
Resistance ≥ 3 CLSI subclasses*
No resistance detected 
At least ACSSuTAuCf§
At least ACSSuT† 
Year
CLSI: Clinical and Laboratory Standards Institute
ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole
ACSSuTAuCf: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftiofur 
Resistance ≥ 4 CLSI subclasses*
Resistance ≥ 2 CLSI subclasses*
Resistance ≥ 1 CLSI subclass*
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5. Campylobacter 
 
Table 5.01: Frequency of Campylobacter species isolated in NARMS, 2007 
N (%)
Campylobacter jejuni 992 (90.2%)
Campylobacter coli 105 (9.5%)
Other 3 (0.3%)
Total 1100 (100.0%)
Species 2007
 
 
 
Table 5.02: Minimum inhibition concentrations (MICs) and resistance of Campylobacter isolates to 
antimicrobial agents, 2007 (N=1100) 
 
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin < 0.1 0.6 [0.3–1.3] 2.5 33.7 55.5 7.2 0.4 < 0.1 0.6
Ketolide Telithromycin 0.6 1.5 [0.8–2.4] 0.7 14.1 35.4 31.5 13.0 3.2 0.6 1.5
Macrolides Azithromycin 0.0 2.0 [1.3–3.0] 1.3 24.0 45.4 21.5 5.5 0.3 0.1 2.0
Erythromycin 0.0 2.0 [1.3–3.0] 0.3 6.1 38.8 30.7 15.8 5.4 0.9 0.1 1.9
Quinolones Ciprofloxacin 0.2 26.0 [23.4–28.7] 2.3 42.5 22.1 5.5 1.5 0.2 1.5 10.3 8.5 4.2 1.2 0.3
Nalidixic acid 0.4 26.5 [23.9–29.2] 56.0 14.9 2.3 0.4 2.4 24.1
Phenicols Florfenicol†† N/A 0.0 [0.0–0.3] 0.3 22.5 61.1 13.5 2.7
Tetracyclines Tetracycline < 0.1 44.3 [41.4–47.4] 3.5 24.5 17.0 6.1 3.4 0.7 0.4 < 0.1 0.8 2.9 12.0 28.6
Lincosamides Clindamycin 0.3 1.7 [1.0–2.7] 1.3 25.8 41.2 19.5 7.2 2.5 0.6 0.3 0.3 0.9 0.5
*
†
‡
§
¶
**
††
Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I):  Rank 1, Critically Important; Rank 2, Highly Important; Rank 3, Important
CLSI: Clinical and Laboratory Standards Institute 
Percent of isolates w ith intermediate susceptibility, N/A if  no MIC range of intermediate susceptibility exists
Percent of isolates that w ere resistant
95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Clopper-Pearson exact method.  The 95% CI is presented to summarize uncertainly in the observed resistance (R%).
The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in 
the shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the low est tested concentrations represent the precentages 
of isolates w ith MICs equal to or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
Only a susceptible breakpoint (≤ 4 μg/ml) has been established. In this report, isolates w ith an MIC ≥ 8 μg/ml are categorized as resistant
% of isolates Percent of all isolates w ith MIC (µg/mL)**
CLSI† Antimicrobial Class Antimicrobial Agent
III
II
I
Rank*
 
Figure 6.01: Antimicrobial resistance pattern for Campylobacter, 2007 
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Table 5.03: Percentage and number of Campylobacter isolates resistant to antimicrobial agents, 1998–2007 
 
Year 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Total Isolates 310 317 324 384 354 328 347 890 816 1100
CLSI† Antimicrobial
Class
Antibiotic
(Resistance breakpoint)
Aminoglycosides Gentamicin 0.3% 0.0% 0.3% 0.0% 0.0% 0.3% 0.3% 0.7% 0.1% 0.6%
(MIC ≥ 8) 1 0 1 0 0 1 1 6 1 7
Ketolides Telithromycin Not Not Not Not Not Not Not 1.0% 1.6% 1.5%
(MIC ≥ 16) Tested Tested Tested Tested Tested Tested Tested 9 13 16
Macrolides Azithromycin 0.6% 2.2% 1.9% 2.1% 2.0% 0.9% 0.6% 1.9% 1.7% 2.0%
(MIC ≥ 8) 2 7 6 8 7 3 2 17 14 22
Erythromycin 1.0% 1.9% 1.2% 2.1% 1.4% 0.9% 0.3% 1.8% 1.7% 2.0%
(MIC ≥ 32) 3 6 4 8 5 3 1 16 14 22
Quinolones Ciprofloxacin 13.9% 18.3% 14.8% 19.5% 20.1% 17.7% 19.0% 21.7% 19.6% 26.0%
(MIC ≥ 4) 43 58 48 75 71 58 66 193 160 286
Nalidixic acid 16.8% 21.1% 16.7% 20.3% 20.6% 18.9% 19.6% 22.4% 20.1% 26.5%
(MIC ≥ 64) 52 67 54 78 73 62 68 199 164 291
Phenicols Chloramphenicol 2.9% 0.6% 0.0% 0.3% 0.3% 0.0% 1.4% Not Not Not
(MIC ≥ 32) 9 2 0 1 1 0 5 Tested Tested Tested
Florfenicol‡ Not Not Not Not Not Not Not 0.6% 0.0% 0.0%
Susceptible breakpoint: (MIC ≤ 4) Tested Tested Tested Tested Tested Tested Tested 5 0 0
Tetracyclines Tetracycline 45.5% 43.8% 38.3% 40.9% 41.2% 38.4% 46.1% 40.6% 46.0% 44.4%
(MIC ≥ 16) 141 139 124 157 146 126 160 361 375 488
Lincosamides Clindamycin 1.3% 1.3% 0.9% 2.1% 2.0% 0.6% 2.0% 1.5% 2.0% 1.7%
(MIC ≥ 8) 4 4 3 8 7 2 7 13 16 19
*
†
‡
Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I):  Rank 1, Critically Important; Rank 2, Highly Important; Rank 3, 
Important
CLSI: Clinical and Laboratory Standards Institute 
Only a susceptible breakpoint (≤ 4 μg/ml) has been established. In this report, isolates with an MIC ≥ 8 μg/ml are categorized as resistant
Rank*
I
II
III
 
Table 5.04: Resistance patterns of Campylobacter isolates, 1998–2007 
 
 
1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
310 317 324 384 354 328 347 890 816 1100
% % % % % % % % % %
n n n n n n n n n n
45.2% 47.3% 52.2% 49.2% 48.3% 50.9% 46.1% 48.4% 43.9% 45.2%
140 150 169 189 171 167 160 431 358 497
54.8% 52.7% 47.8% 50.8% 51.7% 49.1% 53.9% 51.6% 56.1% 54.8%
170 167 155 195 183 161 187 459 458 603
9.7% 13.6% 8.0% 13.3% 12.7% 8.5% 14.1% 13.6% 12.0% 17.5%
30 43 26 51 45 28 49 121 98 192
2.6% 1.6% 0.9% 1.6% 1.1% 0.9% 1.2% 1.5% 1.5% 1.7%
8 5 3 6 4 3 4 13 12 19
0.3% 0.9% 0.3% 0.3% 0.0% 0.3% 0.3% 0.3% 0.5% 0.9%
1 3 1 1 0 1 1 3 4 10
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
0 0 0 0 0 0 0 0 0 0
* CLSI: Clinical and Laboratory Standards Institute 
Resistance ≥ 3 CLSI classes*
Resistance ≥ 4 CLSI classes*
Resistance ≥ 5 CLSI classes*
Resistance ≥ 2 CLSI classes*
No resistance detected 
 
Resistance ≥ 1 CLSI class*
Year
Total Isolates
Table 5.05: Minimum inhibitory concentrations (MICs) and resistance of Campylobacter jejuni isolates to 
antimicrobial agents, 2007, (N=992) 
 
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin 0.1 0.7 [0.3–1.4] 2.7 35.7 55.1 5.4 0.2 0.1 0.7
Ketolide Telithromycin 0.3 1.0 [0.5–1.8] 0.8 14.1 37.1 32.7 12.1 1.9 0.3 1.0
Macrolides Azithromycin 0.0 1.6 [0.9–2.6] 1.4 25.6 47.9 19.4 3.9 0.1 0.1 1.6
Erythromycin 0.0 1.6 [0.9–2.6] 0.3 6.7 41.4 31.3 14.7 3.7 0.3 0.1 1.5
Quinolones Ciprofloxacin 0.2 25.8 [23.1–28.6] 2.3 44.3 21.9 4.8 0.7 0.2 1.4 10.5 7.9 4.4 1.3 0.3
Nalidixic acid 0.4 26.1 [23.4–29.0] 58.2 13.6 1.7 0.4 1.8 24.3
Phenicols Florfenicol†† N/A 0.0 [0.0–0.4] 0.3 23.3 62.8 10.8 2.8
Tetracyclines Tetracycline 0.1 44.7 [41.6–47.9] 3.7 26.3 16.0 5.5 2.7 0.5 0.3 0.1 0.7 3.1 12.7 28.2
Lincosamides Clindamycin 0.1 1.3 [0.7–2.2] 1.3 27.9 43.2 18.4 5.5 1.6 0.5 0.1 0.3 0.6 0.4
*
†
‡
§
¶
**
††
I
II
III
Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I):  Rank 1, Critically Important; Rank 2, Highly Important; Rank 3, Important
CLSI: Clinical and Laboratory Standards Institute 
Percent of isolates w ith intermediate susceptibility, N/A if  no MIC range of intermediate susceptibility exists
Percent of isolates that w ere resistant
95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Clopper-Pearson exact method.  The 95% CI is presented to summarize uncertainly in the observed resistance (R%).
The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in 
the shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the low est tested concentrations represent the precentages 
of isolates w ith MICs equal to or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
Only a susceptible breakpoint (≤ 4 μg/ml) has been established. In this report, isolates w ith an MIC ≥ 8 μg/ml are categorized as resistant
% of isolates Percent of all isolates w ith MIC (µg/mL)**
CLSI† Antimicrobial Class Antimicrobial AgentRank*
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Figure 6.02: Antimicrobial resistance pattern for Campylobacter jejuni, 2007 
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Table 5.06: Percentage and number of Campylobacter jejuni isolates resistant to antimicrobial agents, 
1998–2007 
Year 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Total Isolates 297 293 306 365 329 303 320 791 709 992
Rank*
CLSI† Antimicrobial
Class
Antibiotic
(Resistance breakpoint)
Aminoglycosides Gentamicin 0.3% 0.0% 0.0% 0.0% 0.0% 0.0% 0.3% 0.5% 0.0% 0.7%
(MIC ≥ 8) 1 0 0 0 0 0 1 4 0 7
Ketolides Telithromycin Not Not Not Not Not Not Not 0.6% 0.8% 1.0%
(MIC ≥ 16) Tested Tested Tested Tested Tested Tested Tested 5 6 10
Macrolides Azithromycin 0.3% 1.7% 1.6% 1.9% 1.8% 0.3% 0.6% 1.8% 0.8% 1.6%
(MIC ≥ 8) 1 5 5 7 6 1 2 14 6 16
Erythromycin 0.7% 1.4% 1.0% 1.9% 1.2% 0.3% 0.3% 1.6% 0.8% 1.6%
(MIC ≥ 32) 2 4 3 7 4 1 1 13 6 16
Quinolones Ciprofloxacin 13.8% 17.7% 14.7% 18.4% 20.7% 17.2% 18.1% 21.5% 19.5% 25.8%
(MIC ≥ 4) 41 52 45 67 68 52 58 170 138 256
Nalidixic acid 15.5% 20.1% 16.0% 18.9% 21.3% 17.8% 18.4% 21.9% 19.0% 26.1%
(MIC ≥ 64) 46 59 49 69 70 54 59 173 135 259
Phenicols Chloramphenicol 1.0% 0.7% 0.0% 0.3% 0.3% 0.0% 1.6% Not Not Not
(MIC ≥ 32) 3 2 0 1 1 0 5 Tested Tested Test
Florfenicol
 
ed
‡ Not Not Not Not Not Not Not 0.5% 0.0% 0.0%
Susceptible breakpoint: (MIC ≤ 4) Tested Tested Tested Tested Tested Tested Tested 4 0 0
Tetracyclines Tetracycline 46.1% 45.4% 39.2% 40.3% 41.3% 38.3% 46.9% 41.8% 47.4% 44.8%
(MIC ≥ 16) 137 133 120 147 136 116 150 331 336 444
Lincosamides Clindamycin 1.0% 0.7% 0.7% 1.9% 1.8% 0.0% 2.2% 1.1% 1.0% 1.3%
(MIC ≥ 8) 3 2 2 7 6 0 7 9 7 13
*
†
‡
Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I):  Rank 1, Critically Important; Rank 2, Highly Important; Rank 3, 
Important
CLSI: Clinical and Laboratory Standards Institute 
Only a susceptible breakpoint (≤ 4 μg/ml) has been established. In this report, isolates with an MIC ≥ 8 μg/ml are categorized as resistant
I
II
III
 
Table 5.07: Minimum inhibitory concentrations (MICs) and resistance of Campylobacter coli isolates to 
antimicrobial agents, 2007 (N=105) 
  
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin 0.0 0.0 [0.0–3.5] 14.3 61.0 23.8 1.0
Ketolide Telithromycin 3.8 5.7 [2.1–12.0] 14.3 18.1 21.9 21.0 15.2 3.8 5.7
Macrolides Azithromycin 0.0 5.7 [2.1–12.0] 8.6 21.9 41.0 21.0 1.9 5.7
Erythromycin 0.0 5.7 [2.1–12.0] 1.0 15.2 25.7 24.8 21.0 6.7 5.7
Quinolones Ciprofloxacin 0.0 28.6 [20.2–38.2] 1.9 25.7 23.8 12.4 7.6 2.9 8.6 15.2 1.9
Nalidixic acid 0.0 30.5 [21.9–40.2] 35.2 27.6 6.7 7.6 22.9
Phenicols Florfenicol†† N/A 0.0 [0.0–3.5] 15.2 44.8 38.1 1.9
Tetracyclines Tetracycline 0.0 41.9 [32.3–51.9] 1.9 5.7 26.7 10.5 9.5 2.9 1.0 1.9 1.0 5.7 33.3
Lincosamides Clindamycin 1.9 5.7 [2.1–12.0] 1.0 6.7 21.0 28.6 22.9 10.5 1.9 1.9 3.8 1.9
*
†
‡
§
¶
**
††
I
II
III
Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I):  Rank 1, Critically Important; Rank 2, Highly Important; Rank 3, Important
CLSI: Clinical and Laboratory Standards Institute 
Percent of isolates w ith intermediate susceptibility, N/A if  no MIC range of intermediate susceptibility exists
Percent of isolates that w ere resistant
95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Clopper-Pearson exact method.  The 95% CI is presented to summarize uncertainly in the observed resistance (R%).
The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in 
the shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the low est tested concentrations represent the precentages 
of isolates w ith MICs equal to or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
Only a susceptible breakpoint (≤ 4 μg/ml) has been established. In this report, isolates w ith an MIC ≥ 8 μg/ml are categorized as resistant
% of isolates Percent of all isolates w ith MIC (µg/mL)**
CLSI† Antimicrobial Class Antimicrobial AgentRank*
 
Figure 6.03: Antimicrobial resistance pattern for Campylobacter coli, 2007 
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Table 5.08: Percentage and number of Campylobacter coli isolates resistant to antimicrobial agents, 1998–
2007 
 
 
 
  
Year 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Total Isolates 8 20 12 17 25 22 26 98 97 105
CLSI† Antimicrobial
Class
Antibiotic
(Resistance breakpoint)
Aminoglycosides Gentamicin 0.0% 0.0% 8.3% 0.0% 0.0% 4.5% 0.0% 2.0% 1.0% 0.0%
(MIC ≥ 8) 0 0 1 0 0 1 0 2 1 0
Ketolides Telithromycin Not Not Not Not Not Not Not 4.1% 7.2% 5.7%
(MIC ≥ 16) Tested Tested Tested Tested Tested Tested Tested 4 7 6
Macrolides Azithromycin 12.5% 10.0% 8.3% 5.9% 4.0% 9.1% 0.0% 3.1% 8.2% 5.7%
(MIC ≥ 8) 1 2 1 1 1 2 0 3 8 6
Erythromycin 12.5% 10.0% 8.3% 5.9% 4.0% 9.1% 0.0% 3.1% 8.2% 5.7%
(MIC ≥ 32) 1 2 1 1 1 2 0 3 8 6
Quinolones Ciprofloxacin 0.0% 30.0% 25.0% 47.1% 12.0% 22.7% 30.8% 23.5% 21.6% 28.6%
(MIC ≥ 4) 0 6 3 8 3 5 8 23 21 30
Nalidixic acid 50.0% 30.0% 25.0% 47.1% 12.0% 22.7% 34.6% 26.5% 23.7% 30.5%
(MIC ≥ 64) 4 6 3 8 3 5 9 26 23 32
Phenicols Chloramphenicol 37.5% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% Not Not Not
(MIC ≥ 32) 3 0 0 0 0 0 0 Tested Tested Tested
Florfenicol‡ Not Not Not Not Not Not Not 1.0% 0.0% 0.0%
Susceptible breakpoint: (MIC ≤ 4) Tested Tested Tested Tested Tested Tested Tested 1 0 0
Tetracyclines Tetracycline 50.0% 30.0% 25.0% 58.8% 40.0% 45.5% 38.5% 30.6% 39.2% 41.9%
(MIC ≥ 16) 4 6 3 10 10 10 10 30 38 44
Lincosamides Clindamycin 12.5% 10.0% 8.3% 5.9% 4.0% 9.1% 0.0% 4.1% 9.3% 5.7%
(MIC ≥ 8) 1 2 1 1 1 2 0 4 9 6
*
†
‡
Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I):  Rank 1, Critically Important; Rank 2, Highly Important; Rank 3, 
Important
CLSI: Clinical and Laboratory Standards Institute 
Only a susceptible breakpoint (≤ 4 μg/ml) has been established. In this report, isolates with an MIC ≥ 8 μg/ml are categorized as resistant
II
I
Rank*
III
IS R
REFERENCES 
 
 
References 
 
CDC. National Antimicrobial Resistance Monitoring System for Enteric Bacteria (NARMS): 2005 Human 
Isolates Final Report. Atlanta, Georgia: U.S. Department of Health and Human Services, CDC, 2008. 
 
Clinical and Laboratory Standards Institute. Methods for Antimicrobial Dilution and Disk Susceptibility Testing 
of Infrequently Isolated or Fastidious Bacteria: Approved Guideline. CLSI Document M45-A. CLSI,  Wayne, 
Pennsylvania, 2006. 
 
Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility 
Testing; Nineteenth Informational Supplement. CLSI Document M100-S19. CLSI,  Wayne, Pennsylvania, 
2009. 
 
 Clinical and Laboratory Standards Institute.  Methods for Dilution Antimicrobial Susceptibility Tests for 
Bacteria that Grow Aerobically;  Approved Standard-Eighth Edition.  CLSI Document M07-A8.  CLSI,   
Wayne, Pennsylvania, 2009. 
 
 Clinical and Laboratory Standards Institute.  Performance Standards for Antimicrobial Disk and Dilution 
Susceptibility Tests for Bacteria Isolated from Animals;  Approved Standard-Third Edition.  CLSI Document 
M31-A3.  CLSI,  Wayne, Pennsylvania, 2008. 
  
Fleiss JL, Levin B, Paik MC. Statistical Methods in for Rates and Proportions. In: Shewart WA, Wilks SS, eds. 
Wiley Series in Probability and Statistics. Published Online; 2004.  
 
Gonzalez, I, Grant KA, Richardson PT, Park SF, Collins MD. Specific identification of the enteropathogens 
Campylobacter jejuni and Campylobacter coli by using a PCR test based on the ceuE gene encoding a 
putative virulence determinant. Journal of Clinical Microbiology 1997; 35:759-63. 
 
Linton D, Lawson AJ, Owen RJ, Stanley J. PCR detection, identification to species level, and fingerprinting of 
Campylobacter jejuni and Campylobacter coli direct from diarrheic samples. Journal of Clinical Microbiology 
1997; 35:2568-72. 
 
Linton D, Owen RJ, Stanley J. Rapid Indentification by PCR of the genus Campylobacter and of five 
Campylobacter species enteropathogenic for man and animals. Research in Microbiology 1996;147:707-718. 
 
Pruckler, J., et al., Comparison of four real-time PCR methods for the identification of the genus 
Campylobacter and speciation of C. jejuni and C. coli.  ASM 106th General meeting; Poster C282. 
 
World Health Organization (WHO).  Critically Important Antimicrobials for Human Medicine.  Report of the 
Second WHO Expert Meeting.  Switzerland, 2007. 
 
 
  
   
  
58 
59 
NARMS Publications in 2007 
 
 
Aarestrup FM, Hendriksen RS, Lockett J, Gay K, Teates K, McDermott PF, et al. International spread of 
multidrug-resistant Salmonella Schwarzengrund in food products. Emerging infectious diseases. 2007 
May;13(5):726-31. 
 
Nelson JM, Chiller TM, Powers JH, and Angulo FJ. Fluoroquinolone-resistant Campylobacter species and the 
withdrawal of fluoroquinolones from use in poultry: A public health success story. Clin Infect Dis. April 
2007;44(7):977-80 
 
Stevenson JE, Gay K, Barrett TJ, Medalla F, Chiller TM, Angulo FJ. Increase in nalidixic acid resistance among 
non-Typhi Salmonella enterica isolates in the United States from 1996 to 2003. Antimicrobial agents and 
chemotherapy. 2007 Jan;51(1):195-7. 
 
Whichard JM, Gay K, Stevenson JE, Joyce KJ, Cooper KL, Omondi M, et al. Human Salmonella and concurrent 
decreased susceptibility to quinolones and extended-spectrum cephalosporins. Emerging infectious diseases. 
2007 Nov;13(11):1681-8. 
 
Whichard, J.M., Gay, K., White, D.G., Chiller, T.M. Surveillance for antimicrobial resistance among foodborne 
bacteria: the U.S. approach. p. 79-92 in M’ikanatha, N.M., Lynfield, R., Van Beneden, C.A. and de Valk, H. (ed.) 
Infectious Disease Surveillance. Blackwell: Malden, Massachusetts. 2007. 
  
APPENDIX A 
Summary of Escherichia coli Resistance Surveillance Pilot Study, 2007 
 
 
 
 
 
Frederick Angulo, Ezra Barzilay, Patricia Griffin, Amy Krueger, Rebecca Howie, Kathryn Lupoli, 
 Kevin Joyce, Felicita Medalla  
Foodborne and Diarrheal Diseases Branch, Division of Bacterial and Mycotic Diseases 
National Center for Infectious Diseases 
 
Participating State and Local Health Departments 
 
 
Michigan Department of Community Health and William Beaumont Hospital 
Sue Donabedian, Mary Beth Perry, Mary Thill, Mark Zervos 
 
Centers for Disease Control and Prevention 
E. COLI WORKING GROUP 
 
 
 
 
INTRODUCTION 
 
Escherichia coli is a Gram–negative coccobacillus bacterium that is part of the intestinal flora of humans and 
other animals. Because antimicrobial resistance genes commonly reside in mobile genetic elements that can be 
transferred horizontally to other bacteria, antimicrobial–resistant bacteria of the intestinal flora, including E. coli, 
constitute an important reservoir of resistance genes for pathogenic bacteria of humans and other animals. 
Furthermore, when introduced into a normally sterile site, E. coli is an important cause of infections, including 
septicemia, urinary tract infections, and wound infections. The human intestinal tract is the predominant source of 
E. coli causing these infections. Antimicrobial resistance among E. coli causing such infections complicates 
treatment options. 
 
The use of antimicrobial agents creates a selective pressure for the emergence and dissemination of resistant 
bacteria. Use of antimicrobial agents in food animals selects resistant bacteria, including resistant E. coli in the 
intestinal tract of food animals. These resistant bacteria can be transmitted to humans through the food supply. 
Therefore, monitoring resistance in E. coli isolated from the intestinal flora of humans and animals is important to 
determining the role of these bacteria as human pathogens and as reservoirs of resistance determinants for 
human pathogens. The E. coli Resistance Surveillance Pilot is designed to determine the prevalence of 
resistance to clinically important antimicrobial agents among E. coli isolated from persons in the community. 
 
SUMMARY OF 2007 SURVEILLANCE DATA 
 
Background 
 
Beginning in 2004, NARMS began to prospectively monitor the prevalence of antimicrobial resistance of E. coli 
isolated from human stool samples in two sites: Maryland and Michigan.  
 
 
 
60 
61 
SURVEILLANCE AND LABORATORY TESTING METHODS 
 
In 2007, Michigan was the sole participant in the study.  Michigan cultured 10 human stool samples, from 
outpatients, each month for E. coli using Eosin Methylene Blue agar. One E. coli isolate, if present, from each 
stool sample was sent to CDC for susceptibility testing to antimicrobial agents using broth microdilution 
(Sensititre®) to determine the minimum inhibitory concentration (MIC) for each of 15 antimicrobial agents: 
amikacin, ampicillin, amoxicillin-clavulanic acid, cefoxitin, ceftiofur, ceftriaxone, chloramphenicol, ciprofloxacin, 
gentamicin, kanamycin, nalidixic acid, streptomycin, sulfonamides, tetracycline, and trimethoprim-
sulfamethoxazole (Table A.01).  
 
Interpretive criteria from CLSI were used (Table A.01). The 95% CIs for the percentage of resistant isolates 
calculated using the Clopper-Pearson exact method, are included in the MIC distribution tables. Similarly, 
multiclass resistance by CLSI antimicrobial class was defined as resistance to two or more classes. 
 
RESULTS 
 
In 2007, CDC received 68 stool samples, of these, 66 (97%) were viable E. coli isolates (Table A.02). MIC was 
determined for E. coli isolates for 15 antimicrobial agents (Table A.03). 
 
Of the E. coli isolates, 24.2% were resistant to sulfonamides; 21.2%, to ampicillin; 21.2% to tetracycline; and 
10.6% to nalidixic acid (Table A.04). 
 
In 2007, 24.2% of E. coli isolates were resistant to two or more CLSI classes, and 4.5% were resistant to five or 
more CLSI classes (Table A.05).  
 
Multidrug-Resistant E. coli 
 
• 24.2% of 66 E. coli isolates tested were resistant to two or more classes of antimicrobial agents. 
• 4.5% of 66 E. coli isolates tested were resistant to five or more classes of antimicrobial agents. 
 
Clinically Important Resistance 
 
Antimicrobial agents commonly used to treat serious E. coli infections in humans include third-generation 
cephalosporins and fluoroquinolones. 
• 0.0% of 66 E. coli isolates were resistant to ceftiofur (Table A.04). 
• 7.6% of 66 E. coli isolates were resistant to ciprofloxacin (Table A.04). 
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Susceptible Intermediate Resistant
Amikacin 0.5 – 64 ≤16 32 ≥64
Gentamicin 0.25 – 16 ≤4 8 ≥16
Kanamycin 8 – 64 ≤16 32 ≥64
Streptomycin 32 – 64 ≤32  ≥64
β –lactam / β-lactamase inhibitor 
combinations Amoxicillin–Clavulanic acid 1/0.5 – 32/16 ≤8/4 16/8 ≥32/16
Cefoxitin 0.5 – 32 ≤8 16 ≥32
Ceftiofur 0.12– 8 ≤2 4 ≥8
Ceftriaxone 0.25 – 64 ≤8 16-32 ≥64
Sulfisoxazole 16 – 256 ≤256 ≥512
Trimethoprim–Sulfamethoxazole 0.12/2.4 – 4/76 ≤2/38 ≥4/76
Penicillins Ampicillin 1 – 32 ≤8 16 ≥32
Phenicols Chloramphenicol 2 – 32 ≤8 16 ≥32
Ciprofloxacin 0.015 – 4 ≤1 2 ≥4
Nalidixic acid 0.5 – 32 ≤16 ≥32
Tetracyclines Tetracycline 4 – 32 ≤4 8 ≥16
MIC Interpretive Standard (µg/mL)CLSI class Antimicrobial Agent  Antimicrobial Agent 
Concentration Range 
(µg/mL)
Aminoglycosides
Quinolones
Cephems
Folate pathway inhibitors
 
Table A.02: Minimum inhibition concentrations (MICs) and resistance of Escherichia coli isolates to 
antimicrobial agents, 2007 (N=66) 
 
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Amikacin 0.0 0.0 [0.0–5.4] 1.5 36.4 56.1 6.1
Gentamicin 0.0 3.0 [0.4–10.5] 13.6 72.7 10.6 3.0
Streptomycin N/A 13.6 [6.4–24.3] 86.4 4.5 9.1
β-lactam/β-lactamase inhibitor 
combinations
Amoxicillin-clavulanic acid 0.0 0.0 [0.0–5.4] 3.0 21.2 53.0 22.7
Cephems Ceftiofur 0.0 0.0 [0.0–5.4] 7.6 59.1 30.3 3.0
Ceftriaxone 0.0 0.0 [0.0–5.4] 100.0
Penicillins Ampicillin 0.0 21.2 [12.1–33.0] 12.1 47.0 19.7 1.5 19.7
Quinolones Ciprof loxacin 0.0 7.6 [2.5–16.8] 84.8 4.5 3.0 7.6
Nalidixic Acid N/A 10.6 [4.4–20.6] 13.6 63.6 9.1 1.5 1.5 10.6
Aminoglycosides Kanamycin 0.0 1.5 [0.0–8.2] 97.0 1.5 1.5
Cephems Cefoxitin 0.0 0.0 [0.0–5.4] 3.0 1.5 34.8 50.0 10.6
Folate pathway inhibitors Sulfisoxazole N/A 24.2 [14.5–36.4] 63.6 9.1 3.0 24.2
Trimethoprim-sulfamethoxazole N/A 15.2 [7.5–26.1] 66.7 15.2 1.5 1.5 15.2
Phenicols Chloramphenicol 1.5 3.0 [0.4–10.5] 45.5 50.0 1.5 1.5 1.5
Tetracyclines Tetracycline 0.0 21.2 [12.1–33.0] 78.8 1.5 3.0 16.7
*
†
‡
§
¶
**
II
I
Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I):  Rank 1, Critically Important; Rank 2, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percent of isolates w ith intermediate susceptibility, N/A if no MIC range of intermediate susceptibility exists
Percent of isolates that w ere resistant
95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Clopper-Pearson exact method.  The 95% CI is presented to summarize uncertainly in the observed resistance (R%).
The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for 
resistance. Numbers in the shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the low est tested concentrations 
represent the precentages of isolates w ith MICs equal to or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
% of isolates Percent of all isolates with MIC (µg/mL)**
CLSI† Antimicrobial Class Antimicrobial AgentRank*
 
 
Figure A.01: Antibiotic resistance pattern for Escherichia coli, 2007 
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Table A.03: Percentage and number of Escherichia coli isolates resistant to antimicrobial agents, 2004–
2007 
 
Year 2004 2005 2006 2007
Total Isolates 151 119 82 66
CLSI† Antimicrobial
Class
Antibiotic
(Resistance breakpoint)
Aminoglycosides Amikacin 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) 0 0 0 0
Gentamicin 2.0% 3.4% 3.7% 3.0%
(MIC ≥ 16) 3 4 3 2
Streptomycin 10.6% 14.3% 7.3% 13.6%
(MIC ≥ 64) 16 17 6 9
Amoxicillin-clavulanic acid 2.6% 4.2% 3.7% 0.0%
(MIC ≥ 32) 4 5 3 0
Cephems Ceftiofur 0.0% 0.8% 0.0% 0.0%
(MIC ≥ 8) 0 1 0 0
Ceftriaxone 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) 0 0 0 0
Penicillins Ampicillin 24.5% 26.1% 28.0% 21.2%
(MIC ≥ 32) 37 31 23 14
Quinolones Ciprofloxacin 3.3% 7.6% 4.9% 7.6%
(MIC ≥ 4) 5 9 4 5
Nalidixic Acid 9.3% 9.2% 11.0% 10.6%
(MIC ≥ 32) 14 11 9 7
Aminoglycosides Kanamycin 2.0% 0.0% 0.0% 1.5%
(MIC ≥ 64) 3 0 0 1
Cephems Cefoxitin 2.6% 0.8% 1.2% 0.0%
(MIC ≥ 32) 4 1 1 0
Folate pathway inhibitors Sulfisoxazole‡ 17.9% 18.4% 17.1% 24.2%
(MIC ≥ 512) 27 21 14 16
Trimethoprim-sulfamethoxazole‡ 11.3% 14.9% 12.2% 15.2%
(MIC ≥ 4) 17 17 10 10
Phenicols Chloramphenicol 1.3% 2.5% 3.7% 3.0%
(MIC ≥ 32) 2 3 3 2
Tetracyclines Tetracycline 13.2% 19.3% 14.6% 21.2%
(MIC ≥ 16) 20 23 12 14
*
†
‡
β-lactam/β-lactamase inhibitor 
combinations
Rank*
I
II
Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I):  
Rank 1, Critically Important; Rank 2, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Results unavailable for 5 isolates
  
 
64 
Table A.04: Resistance patterns of Escherichia coli isolates, 2004–2007 
 
2004 2005 2006 2007
151 119 82 66
% % % %
n n n n
62.9% 63.0% 62.2% 63.6%
95 75 51 42
37.7% 37.0% 37.8% 36.4%
57 44 31 24
21.9% 23.5% 23.2% 24.2%
33 28 19 16
14.6% 17.6% 18.3% 18.2%
22 21 15 12
6.0% 9.2% 11.0% 10.6%
9 11 9 7
3.3% 7.6% 1.2% 4.5%
5 9 1 3
1.3% 0.8% 0.0% 0.0%
2 1 0 0
1.3% 0.8% 1.2% 1.5%
2 1 1 1
0.0% 0.0% 0.0% 0.0%
0 0 0 0
0.0% 0.0% 0.0% 0.0%
0 0 0 0
* CLSI: Clinical and Laboratory Standards Institute 
†
‡ ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole 
§ ACSSuTAuCf: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftiofur 
At least ACT/S‡
At least ACSSuTAuCf§
At least ceftiofur and nalidixic acid resistant
Resistance ≥3 CLSI classes*
Resistance ≥4 CLSI classes*
Resistance ≥5 CLSI classes*
At least ACSSuT† 
No resistance detected 
ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxa
Resistance ≥2 CLSI classes*
Year
Total Isolates
Resistance ≥1CLSI class*
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